STUDYID,SUBJID,USUBJID,AGE,STR01,STR01N,STR01L,STR02,STR02N,STR02L,TRT01P,TRT01PN,PARAM,PARAMCD,AVAL,CNSR,EVNTDESC,CNSDTDSC,DCTREAS
PSIVISSIG0002,1,PSIVISSIG0002_1,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,301,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2,PSIVISSIG0002_2,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1108,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,3,PSIVISSIG0002_3,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,846,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,4,PSIVISSIG0002_4,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,406,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,5,PSIVISSIG0002_5,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,730,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,6,PSIVISSIG0002_6,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,34,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,7,PSIVISSIG0002_7,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,709,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,8,PSIVISSIG0002_8,62,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,140,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,9,PSIVISSIG0002_9,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,791,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,10,PSIVISSIG0002_10,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,806,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,11,PSIVISSIG0002_11,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1024,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,12,PSIVISSIG0002_12,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,459,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,13,PSIVISSIG0002_13,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1145,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,14,PSIVISSIG0002_14,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,855,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,15,PSIVISSIG0002_15,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1092,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,16,PSIVISSIG0002_16,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1078,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,17,PSIVISSIG0002_17,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,747,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,18,PSIVISSIG0002_18,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,371,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,19,PSIVISSIG0002_19,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,860,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,20,PSIVISSIG0002_20,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,459,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,21,PSIVISSIG0002_21,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,674,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,22,PSIVISSIG0002_22,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,551,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,23,PSIVISSIG0002_23,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,220,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,24,PSIVISSIG0002_24,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,444,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,25,PSIVISSIG0002_25,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,236,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,26,PSIVISSIG0002_26,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,363,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,27,PSIVISSIG0002_27,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,189,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,28,PSIVISSIG0002_28,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,619,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,29,PSIVISSIG0002_29,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,429,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,30,PSIVISSIG0002_30,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,455,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,31,PSIVISSIG0002_31,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,661,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,32,PSIVISSIG0002_32,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,656,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,33,PSIVISSIG0002_33,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,115,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,34,PSIVISSIG0002_34,45,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,241,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,35,PSIVISSIG0002_35,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,907,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,36,PSIVISSIG0002_36,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1313,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,37,PSIVISSIG0002_37,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,869,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,38,PSIVISSIG0002_38,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,34,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,39,PSIVISSIG0002_39,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1729,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,40,PSIVISSIG0002_40,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,225,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,41,PSIVISSIG0002_41,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1423,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,42,PSIVISSIG0002_42,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,563,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,43,PSIVISSIG0002_43,89,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,534,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,44,PSIVISSIG0002_44,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,226,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,45,PSIVISSIG0002_45,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,431,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,46,PSIVISSIG0002_46,71,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,47,PSIVISSIG0002_47,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,630,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,48,PSIVISSIG0002_48,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,172,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,49,PSIVISSIG0002_49,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1437,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,50,PSIVISSIG0002_50,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,980,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,51,PSIVISSIG0002_51,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,803,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,52,PSIVISSIG0002_52,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,515,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,53,PSIVISSIG0002_53,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,460,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,54,PSIVISSIG0002_54,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,73,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,55,PSIVISSIG0002_55,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,453,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,56,PSIVISSIG0002_56,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,459,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,57,PSIVISSIG0002_57,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,251,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,58,PSIVISSIG0002_58,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1348,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,59,PSIVISSIG0002_59,65,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,130,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,60,PSIVISSIG0002_60,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,793,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,61,PSIVISSIG0002_61,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,977,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,62,PSIVISSIG0002_62,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,913,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,63,PSIVISSIG0002_63,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,187,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,64,PSIVISSIG0002_64,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,156,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,65,PSIVISSIG0002_65,47,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,192,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,66,PSIVISSIG0002_66,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,598,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,67,PSIVISSIG0002_67,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,246,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,68,PSIVISSIG0002_68,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,612,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,69,PSIVISSIG0002_69,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,703,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,70,PSIVISSIG0002_70,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,396,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,71,PSIVISSIG0002_71,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1069,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,72,PSIVISSIG0002_72,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,765,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,73,PSIVISSIG0002_73,45,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,239,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,74,PSIVISSIG0002_74,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,247,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,75,PSIVISSIG0002_75,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,936,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,76,PSIVISSIG0002_76,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,684,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,77,PSIVISSIG0002_77,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,195,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,78,PSIVISSIG0002_78,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,233,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,79,PSIVISSIG0002_79,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,891,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,80,PSIVISSIG0002_80,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,411,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,81,PSIVISSIG0002_81,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,764,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,82,PSIVISSIG0002_82,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,755,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,83,PSIVISSIG0002_83,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,761,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,84,PSIVISSIG0002_84,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,805,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,85,PSIVISSIG0002_85,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,241,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,86,PSIVISSIG0002_86,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,745,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,87,PSIVISSIG0002_87,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,437,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,88,PSIVISSIG0002_88,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,572,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,89,PSIVISSIG0002_89,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,511,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,90,PSIVISSIG0002_90,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,952,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,91,PSIVISSIG0002_91,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,801,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,92,PSIVISSIG0002_92,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1305,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,93,PSIVISSIG0002_93,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1887,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,94,PSIVISSIG0002_94,25,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,803,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,95,PSIVISSIG0002_95,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1086,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,96,PSIVISSIG0002_96,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,410,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,97,PSIVISSIG0002_97,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,185,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,98,PSIVISSIG0002_98,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,840,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,99,PSIVISSIG0002_99,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,593,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,100,PSIVISSIG0002_100,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,500,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,101,PSIVISSIG0002_101,87,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,787,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,102,PSIVISSIG0002_102,83,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,685,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,103,PSIVISSIG0002_103,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,333,0,PD,NA,DEATH
PSIVISSIG0002,104,PSIVISSIG0002_104,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,911,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,105,PSIVISSIG0002_105,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1390,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,106,PSIVISSIG0002_106,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,631,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,107,PSIVISSIG0002_107,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,229,0,Death,NA,DEATH
PSIVISSIG0002,108,PSIVISSIG0002_108,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,125,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,109,PSIVISSIG0002_109,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,475,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,110,PSIVISSIG0002_110,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,391,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,111,PSIVISSIG0002_111,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,401,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,112,PSIVISSIG0002_112,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1034,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,113,PSIVISSIG0002_113,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,309,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,114,PSIVISSIG0002_114,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1371,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,115,PSIVISSIG0002_115,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,877,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,116,PSIVISSIG0002_116,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1191,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,117,PSIVISSIG0002_117,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,863,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,118,PSIVISSIG0002_118,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1134,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,119,PSIVISSIG0002_119,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,371,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,120,PSIVISSIG0002_120,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,744,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,121,PSIVISSIG0002_121,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,405,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,122,PSIVISSIG0002_122,70,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,407,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,123,PSIVISSIG0002_123,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,352,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,124,PSIVISSIG0002_124,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,636,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,125,PSIVISSIG0002_125,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1502,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,126,PSIVISSIG0002_126,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1784,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,127,PSIVISSIG0002_127,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,625,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,128,PSIVISSIG0002_128,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,140,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,129,PSIVISSIG0002_129,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,447,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,130,PSIVISSIG0002_130,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1413,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,131,PSIVISSIG0002_131,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,403,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,132,PSIVISSIG0002_132,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,380,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,133,PSIVISSIG0002_133,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,469,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,134,PSIVISSIG0002_134,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,800,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,135,PSIVISSIG0002_135,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1073,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,136,PSIVISSIG0002_136,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,202,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,137,PSIVISSIG0002_137,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,255,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,138,PSIVISSIG0002_138,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,128,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,139,PSIVISSIG0002_139,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,480,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,140,PSIVISSIG0002_140,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,118,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,141,PSIVISSIG0002_141,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1399,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,142,PSIVISSIG0002_142,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1018,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,143,PSIVISSIG0002_143,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,746,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,144,PSIVISSIG0002_144,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,302,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,145,PSIVISSIG0002_145,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1353,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,146,PSIVISSIG0002_146,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,764,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,147,PSIVISSIG0002_147,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,326,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,148,PSIVISSIG0002_148,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,665,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,149,PSIVISSIG0002_149,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,869,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,150,PSIVISSIG0002_150,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1443,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,151,PSIVISSIG0002_151,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,434,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,152,PSIVISSIG0002_152,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,39,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,153,PSIVISSIG0002_153,92,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1077,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,154,PSIVISSIG0002_154,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,13,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,155,PSIVISSIG0002_155,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,311,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,156,PSIVISSIG0002_156,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,44,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,157,PSIVISSIG0002_157,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,140,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,158,PSIVISSIG0002_158,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,576,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,159,PSIVISSIG0002_159,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1130,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,160,PSIVISSIG0002_160,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,441,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,161,PSIVISSIG0002_161,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1737,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,162,PSIVISSIG0002_162,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,204,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,163,PSIVISSIG0002_163,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,684,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,164,PSIVISSIG0002_164,87,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,793,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,165,PSIVISSIG0002_165,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,935,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,166,PSIVISSIG0002_166,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,127,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,167,PSIVISSIG0002_167,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,446,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,168,PSIVISSIG0002_168,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,837,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,169,PSIVISSIG0002_169,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1182,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,170,PSIVISSIG0002_170,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,637,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,171,PSIVISSIG0002_171,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,266,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,172,PSIVISSIG0002_172,41,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,504,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,173,PSIVISSIG0002_173,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,355,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,174,PSIVISSIG0002_174,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,802,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,175,PSIVISSIG0002_175,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,305,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,176,PSIVISSIG0002_176,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1489,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,177,PSIVISSIG0002_177,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,566,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,178,PSIVISSIG0002_178,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1183,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,179,PSIVISSIG0002_179,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,328,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,180,PSIVISSIG0002_180,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,243,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,181,PSIVISSIG0002_181,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1169,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,182,PSIVISSIG0002_182,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,571,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,183,PSIVISSIG0002_183,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1805,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,184,PSIVISSIG0002_184,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1412,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,185,PSIVISSIG0002_185,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1307,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,186,PSIVISSIG0002_186,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,687,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,187,PSIVISSIG0002_187,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,62,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,188,PSIVISSIG0002_188,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,710,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,189,PSIVISSIG0002_189,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,280,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,190,PSIVISSIG0002_190,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,946,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,191,PSIVISSIG0002_191,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1143,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,192,PSIVISSIG0002_192,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,600,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,193,PSIVISSIG0002_193,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,512,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,194,PSIVISSIG0002_194,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,581,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,195,PSIVISSIG0002_195,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,149,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,196,PSIVISSIG0002_196,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,651,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,197,PSIVISSIG0002_197,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,365,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,198,PSIVISSIG0002_198,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,359,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,199,PSIVISSIG0002_199,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,321,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,200,PSIVISSIG0002_200,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1788,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,201,PSIVISSIG0002_201,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,169,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,202,PSIVISSIG0002_202,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,852,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,203,PSIVISSIG0002_203,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,326,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,204,PSIVISSIG0002_204,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,942,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,205,PSIVISSIG0002_205,87,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,791,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,206,PSIVISSIG0002_206,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1693,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,207,PSIVISSIG0002_207,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1304,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,208,PSIVISSIG0002_208,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,467,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,209,PSIVISSIG0002_209,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,833,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,210,PSIVISSIG0002_210,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,426,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,211,PSIVISSIG0002_211,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,798,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,212,PSIVISSIG0002_212,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,381,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,213,PSIVISSIG0002_213,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1481,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,214,PSIVISSIG0002_214,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,581,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,215,PSIVISSIG0002_215,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,664,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,216,PSIVISSIG0002_216,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,996,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,217,PSIVISSIG0002_217,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,773,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,218,PSIVISSIG0002_218,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,430,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,219,PSIVISSIG0002_219,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1491,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,220,PSIVISSIG0002_220,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,804,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,221,PSIVISSIG0002_221,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,24,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,222,PSIVISSIG0002_222,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,671,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,223,PSIVISSIG0002_223,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,74,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,224,PSIVISSIG0002_224,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1088,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,225,PSIVISSIG0002_225,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1034,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,226,PSIVISSIG0002_226,72,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,726,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,227,PSIVISSIG0002_227,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,550,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,228,PSIVISSIG0002_228,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,465,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,229,PSIVISSIG0002_229,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,647,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,230,PSIVISSIG0002_230,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,734,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,231,PSIVISSIG0002_231,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1393,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,232,PSIVISSIG0002_232,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,342,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,233,PSIVISSIG0002_233,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,255,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,234,PSIVISSIG0002_234,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,761,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,235,PSIVISSIG0002_235,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,772,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,236,PSIVISSIG0002_236,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,607,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,237,PSIVISSIG0002_237,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,421,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,238,PSIVISSIG0002_238,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1021,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,239,PSIVISSIG0002_239,83,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,689,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,240,PSIVISSIG0002_240,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1227,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,241,PSIVISSIG0002_241,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,323,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,242,PSIVISSIG0002_242,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1082,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,243,PSIVISSIG0002_243,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,249,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,244,PSIVISSIG0002_244,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,250,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,245,PSIVISSIG0002_245,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,424,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,246,PSIVISSIG0002_246,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,349,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,247,PSIVISSIG0002_247,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,818,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,248,PSIVISSIG0002_248,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,167,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,249,PSIVISSIG0002_249,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,183,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,250,PSIVISSIG0002_250,48,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1039,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,251,PSIVISSIG0002_251,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,875,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,252,PSIVISSIG0002_252,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,253,PSIVISSIG0002_253,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,124,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,254,PSIVISSIG0002_254,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,806,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,255,PSIVISSIG0002_255,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,624,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,256,PSIVISSIG0002_256,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,739,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,257,PSIVISSIG0002_257,56,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,675,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,258,PSIVISSIG0002_258,60,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,301,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,259,PSIVISSIG0002_259,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1305,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,260,PSIVISSIG0002_260,32,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,241,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,261,PSIVISSIG0002_261,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,673,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,262,PSIVISSIG0002_262,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,241,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,263,PSIVISSIG0002_263,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,813,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,264,PSIVISSIG0002_264,53,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,590,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,265,PSIVISSIG0002_265,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1688,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,266,PSIVISSIG0002_266,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,290,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,267,PSIVISSIG0002_267,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,536,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,268,PSIVISSIG0002_268,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,873,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,269,PSIVISSIG0002_269,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,631,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,270,PSIVISSIG0002_270,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,768,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,271,PSIVISSIG0002_271,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,304,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,272,PSIVISSIG0002_272,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,181,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,273,PSIVISSIG0002_273,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,452,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,274,PSIVISSIG0002_274,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,233,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,275,PSIVISSIG0002_275,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,345,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,276,PSIVISSIG0002_276,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,242,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,277,PSIVISSIG0002_277,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,606,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,278,PSIVISSIG0002_278,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,863,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,279,PSIVISSIG0002_279,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,323,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,280,PSIVISSIG0002_280,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,748,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,281,PSIVISSIG0002_281,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1141,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,282,PSIVISSIG0002_282,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,699,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,283,PSIVISSIG0002_283,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,438,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,284,PSIVISSIG0002_284,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,122,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,285,PSIVISSIG0002_285,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,697,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,286,PSIVISSIG0002_286,56,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,219,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,287,PSIVISSIG0002_287,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,591,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,288,PSIVISSIG0002_288,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,230,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,289,PSIVISSIG0002_289,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,735,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,290,PSIVISSIG0002_290,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,41,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,291,PSIVISSIG0002_291,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,307,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,292,PSIVISSIG0002_292,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1055,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,293,PSIVISSIG0002_293,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,76,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,294,PSIVISSIG0002_294,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,852,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,295,PSIVISSIG0002_295,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1095,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,296,PSIVISSIG0002_296,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1455,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,297,PSIVISSIG0002_297,69,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,570,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,298,PSIVISSIG0002_298,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1193,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,299,PSIVISSIG0002_299,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1165,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,300,PSIVISSIG0002_300,62,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,469,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,301,PSIVISSIG0002_301,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,72,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,302,PSIVISSIG0002_302,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1807,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,303,PSIVISSIG0002_303,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1313,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,304,PSIVISSIG0002_304,39,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,405,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,305,PSIVISSIG0002_305,52,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,238,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,306,PSIVISSIG0002_306,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1472,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,307,PSIVISSIG0002_307,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,279,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,308,PSIVISSIG0002_308,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,667,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,309,PSIVISSIG0002_309,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,552,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,310,PSIVISSIG0002_310,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,156,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,311,PSIVISSIG0002_311,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,356,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,312,PSIVISSIG0002_312,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1484,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,313,PSIVISSIG0002_313,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,173,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,314,PSIVISSIG0002_314,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1916,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,315,PSIVISSIG0002_315,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,676,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,316,PSIVISSIG0002_316,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,655,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,317,PSIVISSIG0002_317,82,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,555,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,318,PSIVISSIG0002_318,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,453,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,319,PSIVISSIG0002_319,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,515,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,320,PSIVISSIG0002_320,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1167,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,321,PSIVISSIG0002_321,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,474,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,322,PSIVISSIG0002_322,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,975,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,323,PSIVISSIG0002_323,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1029,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,324,PSIVISSIG0002_324,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1478,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,325,PSIVISSIG0002_325,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,737,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,326,PSIVISSIG0002_326,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,671,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,327,PSIVISSIG0002_327,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,983,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,328,PSIVISSIG0002_328,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,451,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,329,PSIVISSIG0002_329,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1352,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,330,PSIVISSIG0002_330,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1521,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,331,PSIVISSIG0002_331,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,738,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,332,PSIVISSIG0002_332,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,847,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,333,PSIVISSIG0002_333,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,263,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,334,PSIVISSIG0002_334,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,665,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,335,PSIVISSIG0002_335,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,540,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,336,PSIVISSIG0002_336,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,603,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,337,PSIVISSIG0002_337,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,703,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,338,PSIVISSIG0002_338,70,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,412,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,339,PSIVISSIG0002_339,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,769,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,340,PSIVISSIG0002_340,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1080,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,341,PSIVISSIG0002_341,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,455,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,342,PSIVISSIG0002_342,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,457,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,343,PSIVISSIG0002_343,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,299,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,344,PSIVISSIG0002_344,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,123,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,345,PSIVISSIG0002_345,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,278,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,346,PSIVISSIG0002_346,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,437,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,347,PSIVISSIG0002_347,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1019,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,348,PSIVISSIG0002_348,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,375,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,349,PSIVISSIG0002_349,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1361,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,350,PSIVISSIG0002_350,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1168,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,351,PSIVISSIG0002_351,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,111,0,Death,NA,DEATH
PSIVISSIG0002,352,PSIVISSIG0002_352,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1296,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,353,PSIVISSIG0002_353,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,525,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,354,PSIVISSIG0002_354,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1282,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,355,PSIVISSIG0002_355,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1308,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,356,PSIVISSIG0002_356,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,355,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,357,PSIVISSIG0002_357,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,699,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,358,PSIVISSIG0002_358,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,910,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,359,PSIVISSIG0002_359,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,661,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,360,PSIVISSIG0002_360,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,182,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,361,PSIVISSIG0002_361,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,287,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,362,PSIVISSIG0002_362,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,775,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,363,PSIVISSIG0002_363,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,860,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,364,PSIVISSIG0002_364,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1074,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,365,PSIVISSIG0002_365,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,383,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,366,PSIVISSIG0002_366,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,675,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,367,PSIVISSIG0002_367,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,325,0,PD,NA,DEATH
PSIVISSIG0002,368,PSIVISSIG0002_368,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,915,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,369,PSIVISSIG0002_369,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,354,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,370,PSIVISSIG0002_370,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,803,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,371,PSIVISSIG0002_371,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,337,0,Death,NA,DEATH
PSIVISSIG0002,372,PSIVISSIG0002_372,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,696,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,373,PSIVISSIG0002_373,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,249,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,374,PSIVISSIG0002_374,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,901,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,375,PSIVISSIG0002_375,65,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,133,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,376,PSIVISSIG0002_376,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,357,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,377,PSIVISSIG0002_377,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,355,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,378,PSIVISSIG0002_378,72,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,727,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,379,PSIVISSIG0002_379,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,240,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,380,PSIVISSIG0002_380,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,585,1,Second next-line therapy initiated,Censored at the end date of the next-line therapy,PROGRESSIVE DISEASE
PSIVISSIG0002,381,PSIVISSIG0002_381,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,679,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,382,PSIVISSIG0002_382,37,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,603,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,383,PSIVISSIG0002_383,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,461,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,384,PSIVISSIG0002_384,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,856,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,385,PSIVISSIG0002_385,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1932,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,386,PSIVISSIG0002_386,47,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,188,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,387,PSIVISSIG0002_387,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1131,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,388,PSIVISSIG0002_388,47,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,191,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,389,PSIVISSIG0002_389,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1192,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,390,PSIVISSIG0002_390,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1178,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,391,PSIVISSIG0002_391,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,519,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,392,PSIVISSIG0002_392,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,179,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,393,PSIVISSIG0002_393,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1188,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,394,PSIVISSIG0002_394,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,293,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,395,PSIVISSIG0002_395,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,468,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,396,PSIVISSIG0002_396,52,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,238,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,397,PSIVISSIG0002_397,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,124,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,398,PSIVISSIG0002_398,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,761,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,399,PSIVISSIG0002_399,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,324,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,400,PSIVISSIG0002_400,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1471,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,401,PSIVISSIG0002_401,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,156,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,402,PSIVISSIG0002_402,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,307,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,403,PSIVISSIG0002_403,83,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,676,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,404,PSIVISSIG0002_404,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,294,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,405,PSIVISSIG0002_405,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,454,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,406,PSIVISSIG0002_406,65,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,197,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,407,PSIVISSIG0002_407,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,855,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,408,PSIVISSIG0002_408,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,921,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,409,PSIVISSIG0002_409,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,634,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,410,PSIVISSIG0002_410,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,483,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,411,PSIVISSIG0002_411,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,335,0,Death,NA,DEATH
PSIVISSIG0002,412,PSIVISSIG0002_412,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,704,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,413,PSIVISSIG0002_413,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,748,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,414,PSIVISSIG0002_414,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,344,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,415,PSIVISSIG0002_415,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,678,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,416,PSIVISSIG0002_416,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1239,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,417,PSIVISSIG0002_417,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,968,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,418,PSIVISSIG0002_418,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1371,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,419,PSIVISSIG0002_419,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,721,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,420,PSIVISSIG0002_420,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,458,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,421,PSIVISSIG0002_421,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,692,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,422,PSIVISSIG0002_422,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,182,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,423,PSIVISSIG0002_423,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,357,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,424,PSIVISSIG0002_424,56,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,674,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,425,PSIVISSIG0002_425,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1192,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,426,PSIVISSIG0002_426,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,555,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,427,PSIVISSIG0002_427,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,575,1,Second next-line therapy initiated,Censored at the end date of the next-line therapy,PROGRESSIVE DISEASE
PSIVISSIG0002,428,PSIVISSIG0002_428,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,934,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,429,PSIVISSIG0002_429,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,553,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,430,PSIVISSIG0002_430,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,68,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,431,PSIVISSIG0002_431,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,741,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,432,PSIVISSIG0002_432,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,35,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,433,PSIVISSIG0002_433,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1887,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,434,PSIVISSIG0002_434,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,847,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,435,PSIVISSIG0002_435,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,354,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,436,PSIVISSIG0002_436,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,394,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,437,PSIVISSIG0002_437,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,575,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,438,PSIVISSIG0002_438,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,289,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,439,PSIVISSIG0002_439,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1159,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,440,PSIVISSIG0002_440,92,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1072,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,441,PSIVISSIG0002_441,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,865,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,442,PSIVISSIG0002_442,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,777,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,443,PSIVISSIG0002_443,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,244,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,444,PSIVISSIG0002_444,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,153,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,445,PSIVISSIG0002_445,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,33,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,446,PSIVISSIG0002_446,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,737,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,447,PSIVISSIG0002_447,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,471,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,448,PSIVISSIG0002_448,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,630,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,449,PSIVISSIG0002_449,84,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,139,0,Death,NA,DEATH
PSIVISSIG0002,450,PSIVISSIG0002_450,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1298,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,451,PSIVISSIG0002_451,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,182,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,452,PSIVISSIG0002_452,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,590,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,453,PSIVISSIG0002_453,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,386,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,454,PSIVISSIG0002_454,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,441,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,455,PSIVISSIG0002_455,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,584,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,456,PSIVISSIG0002_456,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,779,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,457,PSIVISSIG0002_457,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,704,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,458,PSIVISSIG0002_458,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,477,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,459,PSIVISSIG0002_459,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,301,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,460,PSIVISSIG0002_460,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,414,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,461,PSIVISSIG0002_461,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,382,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,462,PSIVISSIG0002_462,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,582,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,463,PSIVISSIG0002_463,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,67,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,464,PSIVISSIG0002_464,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1514,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,465,PSIVISSIG0002_465,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,561,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,466,PSIVISSIG0002_466,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,542,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,467,PSIVISSIG0002_467,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1510,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,468,PSIVISSIG0002_468,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,6,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,469,PSIVISSIG0002_469,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1505,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,470,PSIVISSIG0002_470,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,833,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,471,PSIVISSIG0002_471,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,857,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,472,PSIVISSIG0002_472,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,233,0,Death,NA,DEATH
PSIVISSIG0002,473,PSIVISSIG0002_473,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,571,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,474,PSIVISSIG0002_474,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,481,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,475,PSIVISSIG0002_475,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,831,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,476,PSIVISSIG0002_476,25,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,787,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,477,PSIVISSIG0002_477,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,240,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,478,PSIVISSIG0002_478,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1691,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,479,PSIVISSIG0002_479,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,407,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,480,PSIVISSIG0002_480,92,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1079,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,481,PSIVISSIG0002_481,88,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,349,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,482,PSIVISSIG0002_482,85,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,38,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,483,PSIVISSIG0002_483,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,171,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,484,PSIVISSIG0002_484,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,78,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,485,PSIVISSIG0002_485,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,72,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,486,PSIVISSIG0002_486,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1674,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,487,PSIVISSIG0002_487,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,253,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,488,PSIVISSIG0002_488,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1037,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,489,PSIVISSIG0002_489,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,179,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,490,PSIVISSIG0002_490,65,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,231,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,491,PSIVISSIG0002_491,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,398,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,492,PSIVISSIG0002_492,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,441,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,493,PSIVISSIG0002_493,88,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,341,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,494,PSIVISSIG0002_494,47,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,180,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,495,PSIVISSIG0002_495,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,811,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,496,PSIVISSIG0002_496,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,779,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,497,PSIVISSIG0002_497,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,567,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,498,PSIVISSIG0002_498,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1888,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,499,PSIVISSIG0002_499,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,387,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,500,PSIVISSIG0002_500,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,383,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,501,PSIVISSIG0002_501,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,981,0,PD,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,502,PSIVISSIG0002_502,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,124,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,503,PSIVISSIG0002_503,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,530,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,504,PSIVISSIG0002_504,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,323,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,505,PSIVISSIG0002_505,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,291,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,506,PSIVISSIG0002_506,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,142,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,507,PSIVISSIG0002_507,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,707,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,508,PSIVISSIG0002_508,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,787,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,509,PSIVISSIG0002_509,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,696,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,510,PSIVISSIG0002_510,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,944,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,511,PSIVISSIG0002_511,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1007,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,512,PSIVISSIG0002_512,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,688,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,513,PSIVISSIG0002_513,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,625,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,514,PSIVISSIG0002_514,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,812,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,515,PSIVISSIG0002_515,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,761,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,516,PSIVISSIG0002_516,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1422,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,517,PSIVISSIG0002_517,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,734,0,Death,NA,DEATH
PSIVISSIG0002,518,PSIVISSIG0002_518,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,780,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,519,PSIVISSIG0002_519,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,253,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,520,PSIVISSIG0002_520,52,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,238,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,521,PSIVISSIG0002_521,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,747,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,522,PSIVISSIG0002_522,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,523,PSIVISSIG0002_523,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1476,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,524,PSIVISSIG0002_524,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1291,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,525,PSIVISSIG0002_525,53,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1083,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,526,PSIVISSIG0002_526,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,255,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,527,PSIVISSIG0002_527,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1081,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,528,PSIVISSIG0002_528,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,865,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,529,PSIVISSIG0002_529,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,480,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,530,PSIVISSIG0002_530,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,491,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,531,PSIVISSIG0002_531,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1510,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,532,PSIVISSIG0002_532,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,795,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,533,PSIVISSIG0002_533,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1418,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,534,PSIVISSIG0002_534,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1421,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,535,PSIVISSIG0002_535,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,771,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,536,PSIVISSIG0002_536,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,313,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,537,PSIVISSIG0002_537,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,794,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,538,PSIVISSIG0002_538,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,751,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,539,PSIVISSIG0002_539,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,540,PSIVISSIG0002_540,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,287,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,541,PSIVISSIG0002_541,62,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,257,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,542,PSIVISSIG0002_542,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,269,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,543,PSIVISSIG0002_543,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1416,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,544,PSIVISSIG0002_544,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1073,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,545,PSIVISSIG0002_545,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,211,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,546,PSIVISSIG0002_546,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,770,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,547,PSIVISSIG0002_547,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,617,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,548,PSIVISSIG0002_548,68,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,709,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,549,PSIVISSIG0002_549,48,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1047,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,550,PSIVISSIG0002_550,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,218,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,551,PSIVISSIG0002_551,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,806,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,552,PSIVISSIG0002_552,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,580,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,553,PSIVISSIG0002_553,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,241,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,554,PSIVISSIG0002_554,62,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,140,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,555,PSIVISSIG0002_555,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,701,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,556,PSIVISSIG0002_556,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1170,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,557,PSIVISSIG0002_557,70,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,420,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,558,PSIVISSIG0002_558,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,468,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,559,PSIVISSIG0002_559,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,569,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,560,PSIVISSIG0002_560,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1288,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,561,PSIVISSIG0002_561,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,800,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,562,PSIVISSIG0002_562,56,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,681,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,563,PSIVISSIG0002_563,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,346,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,564,PSIVISSIG0002_564,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,344,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,565,PSIVISSIG0002_565,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,988,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,566,PSIVISSIG0002_566,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,579,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,567,PSIVISSIG0002_567,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,395,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,568,PSIVISSIG0002_568,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,983,0,PD,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,569,PSIVISSIG0002_569,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,408,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,570,PSIVISSIG0002_570,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1404,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,571,PSIVISSIG0002_571,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,247,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,572,PSIVISSIG0002_572,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,943,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,573,PSIVISSIG0002_573,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,298,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,574,PSIVISSIG0002_574,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,423,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,575,PSIVISSIG0002_575,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,292,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,576,PSIVISSIG0002_576,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1314,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,577,PSIVISSIG0002_577,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,913,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,578,PSIVISSIG0002_578,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,698,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,579,PSIVISSIG0002_579,48,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1041,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,580,PSIVISSIG0002_580,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,313,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,581,PSIVISSIG0002_581,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,275,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,582,PSIVISSIG0002_582,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1327,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,583,PSIVISSIG0002_583,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,15,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,584,PSIVISSIG0002_584,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,795,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,585,PSIVISSIG0002_585,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,342,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,586,PSIVISSIG0002_586,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,792,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,587,PSIVISSIG0002_587,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1092,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,588,PSIVISSIG0002_588,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,283,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,589,PSIVISSIG0002_589,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1404,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,590,PSIVISSIG0002_590,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,904,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,591,PSIVISSIG0002_591,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,821,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,592,PSIVISSIG0002_592,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1183,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,593,PSIVISSIG0002_593,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,858,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,594,PSIVISSIG0002_594,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,303,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,595,PSIVISSIG0002_595,64,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1315,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,596,PSIVISSIG0002_596,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,341,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,597,PSIVISSIG0002_597,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,597,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,598,PSIVISSIG0002_598,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,437,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,599,PSIVISSIG0002_599,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,519,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,600,PSIVISSIG0002_600,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,272,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,601,PSIVISSIG0002_601,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,747,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,602,PSIVISSIG0002_602,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,264,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,603,PSIVISSIG0002_603,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,660,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,604,PSIVISSIG0002_604,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1395,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,605,PSIVISSIG0002_605,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,306,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,606,PSIVISSIG0002_606,65,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,234,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,607,PSIVISSIG0002_607,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,340,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,608,PSIVISSIG0002_608,64,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1323,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,609,PSIVISSIG0002_609,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1181,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,610,PSIVISSIG0002_610,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,817,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,611,PSIVISSIG0002_611,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,751,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,612,PSIVISSIG0002_612,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,341,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,613,PSIVISSIG0002_613,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,395,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,614,PSIVISSIG0002_614,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,630,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,615,PSIVISSIG0002_615,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,464,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,616,PSIVISSIG0002_616,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,520,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,617,PSIVISSIG0002_617,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1323,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,618,PSIVISSIG0002_618,47,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,190,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,619,PSIVISSIG0002_619,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,400,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,620,PSIVISSIG0002_620,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,562,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,621,PSIVISSIG0002_621,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,195,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,622,PSIVISSIG0002_622,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,863,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,623,PSIVISSIG0002_623,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,60,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,624,PSIVISSIG0002_624,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,124,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,625,PSIVISSIG0002_625,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,393,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,626,PSIVISSIG0002_626,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,322,0,PD,NA,DEATH
PSIVISSIG0002,627,PSIVISSIG0002_627,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1655,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,628,PSIVISSIG0002_628,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,681,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,629,PSIVISSIG0002_629,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1032,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,630,PSIVISSIG0002_630,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,259,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,631,PSIVISSIG0002_631,58,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,395,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,632,PSIVISSIG0002_632,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,443,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,633,PSIVISSIG0002_633,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,592,1,Second next-line therapy initiated,Censored at the end date of the next-line therapy,PROGRESSIVE DISEASE
PSIVISSIG0002,634,PSIVISSIG0002_634,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,629,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,635,PSIVISSIG0002_635,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1532,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,636,PSIVISSIG0002_636,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,280,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,637,PSIVISSIG0002_637,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,606,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,638,PSIVISSIG0002_638,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,736,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,639,PSIVISSIG0002_639,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,415,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,640,PSIVISSIG0002_640,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,287,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,641,PSIVISSIG0002_641,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,787,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,642,PSIVISSIG0002_642,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,904,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,643,PSIVISSIG0002_643,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,428,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,644,PSIVISSIG0002_644,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,620,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,645,PSIVISSIG0002_645,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,496,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,646,PSIVISSIG0002_646,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1476,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,647,PSIVISSIG0002_647,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,444,1,Ongoing on first next-line therapy,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,648,PSIVISSIG0002_648,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,412,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,649,PSIVISSIG0002_649,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,473,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,650,PSIVISSIG0002_650,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,249,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,651,PSIVISSIG0002_651,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,616,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,652,PSIVISSIG0002_652,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,658,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,653,PSIVISSIG0002_653,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,578,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,654,PSIVISSIG0002_654,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,219,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,655,PSIVISSIG0002_655,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,455,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,656,PSIVISSIG0002_656,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,746,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,657,PSIVISSIG0002_657,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1347,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,658,PSIVISSIG0002_658,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1077,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,659,PSIVISSIG0002_659,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,184,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,660,PSIVISSIG0002_660,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,977,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,661,PSIVISSIG0002_661,65,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,118,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,662,PSIVISSIG0002_662,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,637,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,663,PSIVISSIG0002_663,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1412,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,664,PSIVISSIG0002_664,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,922,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,665,PSIVISSIG0002_665,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,413,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,666,PSIVISSIG0002_666,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,232,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,667,PSIVISSIG0002_667,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,721,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,668,PSIVISSIG0002_668,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,492,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,669,PSIVISSIG0002_669,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,744,0,Death,NA,DEATH
PSIVISSIG0002,670,PSIVISSIG0002_670,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,517,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,671,PSIVISSIG0002_671,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,117,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,672,PSIVISSIG0002_672,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1410,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,673,PSIVISSIG0002_673,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,909,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,674,PSIVISSIG0002_674,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,749,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,675,PSIVISSIG0002_675,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,531,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,676,PSIVISSIG0002_676,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,950,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,677,PSIVISSIG0002_677,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,450,1,Ongoing on first next-line therapy,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,678,PSIVISSIG0002_678,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1040,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,679,PSIVISSIG0002_679,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1042,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,680,PSIVISSIG0002_680,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,986,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,681,PSIVISSIG0002_681,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,239,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,682,PSIVISSIG0002_682,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1171,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,683,PSIVISSIG0002_683,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,670,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,684,PSIVISSIG0002_684,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,577,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,685,PSIVISSIG0002_685,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,249,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,686,PSIVISSIG0002_686,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,645,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,687,PSIVISSIG0002_687,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,269,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,688,PSIVISSIG0002_688,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,291,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,689,PSIVISSIG0002_689,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,238,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,690,PSIVISSIG0002_690,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,248,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,691,PSIVISSIG0002_691,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,467,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,692,PSIVISSIG0002_692,60,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,893,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,693,PSIVISSIG0002_693,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,613,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,694,PSIVISSIG0002_694,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,685,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,695,PSIVISSIG0002_695,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1348,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,696,PSIVISSIG0002_696,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1082,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,697,PSIVISSIG0002_697,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,442,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,698,PSIVISSIG0002_698,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,259,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,699,PSIVISSIG0002_699,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,287,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,700,PSIVISSIG0002_700,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,398,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,701,PSIVISSIG0002_701,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,451,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,702,PSIVISSIG0002_702,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1524,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,703,PSIVISSIG0002_703,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1171,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,704,PSIVISSIG0002_704,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,681,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,705,PSIVISSIG0002_705,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1005,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,706,PSIVISSIG0002_706,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,319,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,707,PSIVISSIG0002_707,60,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,906,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,708,PSIVISSIG0002_708,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,129,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,709,PSIVISSIG0002_709,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,686,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,710,PSIVISSIG0002_710,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1059,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,711,PSIVISSIG0002_711,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,686,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,712,PSIVISSIG0002_712,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1089,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,713,PSIVISSIG0002_713,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,557,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,714,PSIVISSIG0002_714,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,190,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,715,PSIVISSIG0002_715,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,538,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,716,PSIVISSIG0002_716,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,121,0,Death,NA,PROTOCOL DEVIATION
PSIVISSIG0002,717,PSIVISSIG0002_717,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,293,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,718,PSIVISSIG0002_718,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,749,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,719,PSIVISSIG0002_719,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,587,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,720,PSIVISSIG0002_720,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,425,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,721,PSIVISSIG0002_721,37,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,601,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,722,PSIVISSIG0002_722,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,721,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,723,PSIVISSIG0002_723,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1881,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,724,PSIVISSIG0002_724,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,405,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,725,PSIVISSIG0002_725,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,237,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,726,PSIVISSIG0002_726,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,276,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,727,PSIVISSIG0002_727,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,610,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,728,PSIVISSIG0002_728,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,944,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,729,PSIVISSIG0002_729,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,524,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,730,PSIVISSIG0002_730,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,323,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,731,PSIVISSIG0002_731,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,216,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,732,PSIVISSIG0002_732,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,99,0,Death,NA,DEATH
PSIVISSIG0002,733,PSIVISSIG0002_733,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1015,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,734,PSIVISSIG0002_734,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,37,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,735,PSIVISSIG0002_735,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,810,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,736,PSIVISSIG0002_736,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,744,0,Death,NA,DEATH
PSIVISSIG0002,737,PSIVISSIG0002_737,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1475,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,738,PSIVISSIG0002_738,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,435,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,739,PSIVISSIG0002_739,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,675,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,740,PSIVISSIG0002_740,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,948,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,741,PSIVISSIG0002_741,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1311,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,742,PSIVISSIG0002_742,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,118,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,743,PSIVISSIG0002_743,43,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,184,0,PD,NA,PROTOCOL DEVIATION
PSIVISSIG0002,744,PSIVISSIG0002_744,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,505,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,745,PSIVISSIG0002_745,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,721,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,746,PSIVISSIG0002_746,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,630,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,747,PSIVISSIG0002_747,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,67,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,748,PSIVISSIG0002_748,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,367,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,749,PSIVISSIG0002_749,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,407,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,750,PSIVISSIG0002_750,39,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,401,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,751,PSIVISSIG0002_751,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,78,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,752,PSIVISSIG0002_752,61,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,598,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,753,PSIVISSIG0002_753,40,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,177,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,754,PSIVISSIG0002_754,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1207,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,755,PSIVISSIG0002_755,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,556,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,756,PSIVISSIG0002_756,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,555,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,757,PSIVISSIG0002_757,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,258,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,758,PSIVISSIG0002_758,71,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,168,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,759,PSIVISSIG0002_759,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,117,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,760,PSIVISSIG0002_760,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,446,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,761,PSIVISSIG0002_761,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1473,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,762,PSIVISSIG0002_762,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,704,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,763,PSIVISSIG0002_763,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,60,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,764,PSIVISSIG0002_764,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,304,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,765,PSIVISSIG0002_765,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,518,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,766,PSIVISSIG0002_766,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,699,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,767,PSIVISSIG0002_767,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,145,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,768,PSIVISSIG0002_768,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,344,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,769,PSIVISSIG0002_769,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1687,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,770,PSIVISSIG0002_770,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1402,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,771,PSIVISSIG0002_771,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,517,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,772,PSIVISSIG0002_772,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,884,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,773,PSIVISSIG0002_773,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1943,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,774,PSIVISSIG0002_774,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,848,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,775,PSIVISSIG0002_775,69,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,573,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,776,PSIVISSIG0002_776,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,987,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,777,PSIVISSIG0002_777,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,761,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,778,PSIVISSIG0002_778,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1772,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,779,PSIVISSIG0002_779,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,225,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,780,PSIVISSIG0002_780,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,240,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,781,PSIVISSIG0002_781,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,993,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,782,PSIVISSIG0002_782,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,297,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,783,PSIVISSIG0002_783,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,358,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,784,PSIVISSIG0002_784,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,312,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,785,PSIVISSIG0002_785,45,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,257,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,786,PSIVISSIG0002_786,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1467,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,787,PSIVISSIG0002_787,55,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1060,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,788,PSIVISSIG0002_788,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,649,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,789,PSIVISSIG0002_789,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,288,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,790,PSIVISSIG0002_790,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,986,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,791,PSIVISSIG0002_791,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1315,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,792,PSIVISSIG0002_792,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,941,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,793,PSIVISSIG0002_793,85,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,44,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,794,PSIVISSIG0002_794,67,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,915,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,795,PSIVISSIG0002_795,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,433,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,796,PSIVISSIG0002_796,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,294,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,797,PSIVISSIG0002_797,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,709,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,798,PSIVISSIG0002_798,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,169,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,799,PSIVISSIG0002_799,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,507,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,800,PSIVISSIG0002_800,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,308,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,801,PSIVISSIG0002_801,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,947,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,802,PSIVISSIG0002_802,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,299,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,803,PSIVISSIG0002_803,37,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,603,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,804,PSIVISSIG0002_804,35,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,658,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,805,PSIVISSIG0002_805,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,774,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,806,PSIVISSIG0002_806,67,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,910,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,807,PSIVISSIG0002_807,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,88,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,808,PSIVISSIG0002_808,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,451,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,809,PSIVISSIG0002_809,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1221,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,810,PSIVISSIG0002_810,62,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,254,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,811,PSIVISSIG0002_811,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1454,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,812,PSIVISSIG0002_812,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,552,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,813,PSIVISSIG0002_813,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,273,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,814,PSIVISSIG0002_814,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,373,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,815,PSIVISSIG0002_815,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,84,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,816,PSIVISSIG0002_816,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,920,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,817,PSIVISSIG0002_817,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,243,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,818,PSIVISSIG0002_818,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,850,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,819,PSIVISSIG0002_819,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,407,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,820,PSIVISSIG0002_820,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,239,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,821,PSIVISSIG0002_821,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1193,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,822,PSIVISSIG0002_822,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,362,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,823,PSIVISSIG0002_823,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,513,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,824,PSIVISSIG0002_824,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,723,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,825,PSIVISSIG0002_825,46,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,254,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,826,PSIVISSIG0002_826,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,746,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,827,PSIVISSIG0002_827,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1053,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,828,PSIVISSIG0002_828,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,311,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,829,PSIVISSIG0002_829,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,631,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,830,PSIVISSIG0002_830,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,191,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,831,PSIVISSIG0002_831,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1030,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,832,PSIVISSIG0002_832,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,337,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,833,PSIVISSIG0002_833,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,272,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,834,PSIVISSIG0002_834,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,687,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,835,PSIVISSIG0002_835,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,121,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,836,PSIVISSIG0002_836,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,983,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,837,PSIVISSIG0002_837,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,391,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,838,PSIVISSIG0002_838,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,703,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,839,PSIVISSIG0002_839,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,461,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,840,PSIVISSIG0002_840,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,539,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,841,PSIVISSIG0002_841,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,560,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,842,PSIVISSIG0002_842,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,498,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,843,PSIVISSIG0002_843,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,451,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,844,PSIVISSIG0002_844,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,803,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,845,PSIVISSIG0002_845,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,450,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,846,PSIVISSIG0002_846,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,970,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,847,PSIVISSIG0002_847,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,927,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,848,PSIVISSIG0002_848,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,524,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,849,PSIVISSIG0002_849,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,732,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,850,PSIVISSIG0002_850,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,854,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,851,PSIVISSIG0002_851,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,865,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,852,PSIVISSIG0002_852,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1184,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,853,PSIVISSIG0002_853,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,231,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,854,PSIVISSIG0002_854,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,459,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,855,PSIVISSIG0002_855,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,228,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,856,PSIVISSIG0002_856,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1375,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,857,PSIVISSIG0002_857,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,239,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,858,PSIVISSIG0002_858,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,227,0,Death,NA,DEATH
PSIVISSIG0002,859,PSIVISSIG0002_859,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1103,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,860,PSIVISSIG0002_860,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,19,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,861,PSIVISSIG0002_861,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1130,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,862,PSIVISSIG0002_862,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,515,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,863,PSIVISSIG0002_863,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,265,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,864,PSIVISSIG0002_864,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1011,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,865,PSIVISSIG0002_865,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1002,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,866,PSIVISSIG0002_866,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,357,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,867,PSIVISSIG0002_867,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,594,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,868,PSIVISSIG0002_868,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,786,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,869,PSIVISSIG0002_869,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,752,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,870,PSIVISSIG0002_870,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,614,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,871,PSIVISSIG0002_871,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1823,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,872,PSIVISSIG0002_872,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,565,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,873,PSIVISSIG0002_873,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,826,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,874,PSIVISSIG0002_874,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,655,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,875,PSIVISSIG0002_875,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,198,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,876,PSIVISSIG0002_876,61,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,600,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,877,PSIVISSIG0002_877,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1297,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,878,PSIVISSIG0002_878,92,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1067,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,879,PSIVISSIG0002_879,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,298,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,880,PSIVISSIG0002_880,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,188,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,881,PSIVISSIG0002_881,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,264,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,882,PSIVISSIG0002_882,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1289,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,883,PSIVISSIG0002_883,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,347,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,884,PSIVISSIG0002_884,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,248,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,885,PSIVISSIG0002_885,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,483,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,886,PSIVISSIG0002_886,83,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,687,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,887,PSIVISSIG0002_887,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1405,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,888,PSIVISSIG0002_888,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,859,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,889,PSIVISSIG0002_889,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,470,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,890,PSIVISSIG0002_890,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,47,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,891,PSIVISSIG0002_891,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1706,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,892,PSIVISSIG0002_892,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,430,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,893,PSIVISSIG0002_893,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,523,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,894,PSIVISSIG0002_894,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1482,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,895,PSIVISSIG0002_895,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,230,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,896,PSIVISSIG0002_896,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,171,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,897,PSIVISSIG0002_897,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1129,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,898,PSIVISSIG0002_898,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,484,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,899,PSIVISSIG0002_899,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1195,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,900,PSIVISSIG0002_900,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1017,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,901,PSIVISSIG0002_901,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,630,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,902,PSIVISSIG0002_902,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,440,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,903,PSIVISSIG0002_903,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,362,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,904,PSIVISSIG0002_904,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,636,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,905,PSIVISSIG0002_905,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,799,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,906,PSIVISSIG0002_906,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1713,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,907,PSIVISSIG0002_907,53,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1076,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,908,PSIVISSIG0002_908,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,211,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,909,PSIVISSIG0002_909,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1303,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,910,PSIVISSIG0002_910,60,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,309,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,911,PSIVISSIG0002_911,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,746,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,912,PSIVISSIG0002_912,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,550,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,913,PSIVISSIG0002_913,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,297,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,914,PSIVISSIG0002_914,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,508,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,915,PSIVISSIG0002_915,46,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,269,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,916,PSIVISSIG0002_916,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1024,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,917,PSIVISSIG0002_917,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,620,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,918,PSIVISSIG0002_918,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,660,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,919,PSIVISSIG0002_919,47,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,188,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,920,PSIVISSIG0002_920,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1082,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,921,PSIVISSIG0002_921,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,565,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,922,PSIVISSIG0002_922,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1591,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,923,PSIVISSIG0002_923,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1069,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,924,PSIVISSIG0002_924,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,358,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,925,PSIVISSIG0002_925,84,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,142,0,Death,NA,DEATH
PSIVISSIG0002,926,PSIVISSIG0002_926,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,147,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,927,PSIVISSIG0002_927,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,150,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,928,PSIVISSIG0002_928,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,477,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,929,PSIVISSIG0002_929,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1202,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,930,PSIVISSIG0002_930,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,157,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,931,PSIVISSIG0002_931,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,600,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,932,PSIVISSIG0002_932,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1305,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,933,PSIVISSIG0002_933,65,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,186,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,934,PSIVISSIG0002_934,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1317,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,935,PSIVISSIG0002_935,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1087,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,936,PSIVISSIG0002_936,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,829,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,937,PSIVISSIG0002_937,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1785,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,938,PSIVISSIG0002_938,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,292,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,939,PSIVISSIG0002_939,77,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,458,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,940,PSIVISSIG0002_940,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,738,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,941,PSIVISSIG0002_941,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,357,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,942,PSIVISSIG0002_942,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1407,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,943,PSIVISSIG0002_943,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1128,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,944,PSIVISSIG0002_944,68,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,725,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,945,PSIVISSIG0002_945,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,863,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,946,PSIVISSIG0002_946,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,252,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,947,PSIVISSIG0002_947,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,398,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,948,PSIVISSIG0002_948,56,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,221,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,949,PSIVISSIG0002_949,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,420,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,950,PSIVISSIG0002_950,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,761,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,951,PSIVISSIG0002_951,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,247,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,952,PSIVISSIG0002_952,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,239,0,Death,NA,DEATH
PSIVISSIG0002,953,PSIVISSIG0002_953,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,254,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,954,PSIVISSIG0002_954,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,664,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,955,PSIVISSIG0002_955,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,645,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,956,PSIVISSIG0002_956,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,389,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,957,PSIVISSIG0002_957,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,199,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,958,PSIVISSIG0002_958,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,559,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,959,PSIVISSIG0002_959,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1019,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,960,PSIVISSIG0002_960,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,392,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,961,PSIVISSIG0002_961,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,849,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,962,PSIVISSIG0002_962,82,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,563,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,963,PSIVISSIG0002_963,60,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,907,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,964,PSIVISSIG0002_964,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,652,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,965,PSIVISSIG0002_965,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,709,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,966,PSIVISSIG0002_966,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1177,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,967,PSIVISSIG0002_967,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,263,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,968,PSIVISSIG0002_968,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1087,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,969,PSIVISSIG0002_969,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1054,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,970,PSIVISSIG0002_970,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1020,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,971,PSIVISSIG0002_971,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,634,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,972,PSIVISSIG0002_972,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,748,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,973,PSIVISSIG0002_973,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1030,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,974,PSIVISSIG0002_974,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,446,1,Ongoing on first next-line therapy,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,975,PSIVISSIG0002_975,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,110,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,976,PSIVISSIG0002_976,89,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,529,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,977,PSIVISSIG0002_977,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,813,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,978,PSIVISSIG0002_978,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,621,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,979,PSIVISSIG0002_979,32,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,233,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,980,PSIVISSIG0002_980,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,710,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,981,PSIVISSIG0002_981,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,45,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,982,PSIVISSIG0002_982,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,845,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,983,PSIVISSIG0002_983,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,870,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,984,PSIVISSIG0002_984,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,193,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,985,PSIVISSIG0002_985,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,219,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,986,PSIVISSIG0002_986,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,285,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,987,PSIVISSIG0002_987,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1739,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,988,PSIVISSIG0002_988,61,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,598,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,989,PSIVISSIG0002_989,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,304,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,990,PSIVISSIG0002_990,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1071,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,991,PSIVISSIG0002_991,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,736,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,992,PSIVISSIG0002_992,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,468,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,993,PSIVISSIG0002_993,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1161,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,994,PSIVISSIG0002_994,71,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,151,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,995,PSIVISSIG0002_995,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,813,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,996,PSIVISSIG0002_996,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1735,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,997,PSIVISSIG0002_997,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1251,0,Death,NA,DEATH
PSIVISSIG0002,998,PSIVISSIG0002_998,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,844,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,999,PSIVISSIG0002_999,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1467,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1000,PSIVISSIG0002_1000,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,774,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1001,PSIVISSIG0002_1001,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,234,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1002,PSIVISSIG0002_1002,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,645,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1003,PSIVISSIG0002_1003,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,473,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1004,PSIVISSIG0002_1004,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,170,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1005,PSIVISSIG0002_1005,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,971,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1006,PSIVISSIG0002_1006,40,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,172,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1007,PSIVISSIG0002_1007,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1299,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1008,PSIVISSIG0002_1008,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1182,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1009,PSIVISSIG0002_1009,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,469,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1010,PSIVISSIG0002_1010,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1025,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1011,PSIVISSIG0002_1011,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,298,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1012,PSIVISSIG0002_1012,89,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,540,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1013,PSIVISSIG0002_1013,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,351,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1014,PSIVISSIG0002_1014,58,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,410,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1015,PSIVISSIG0002_1015,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,578,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1016,PSIVISSIG0002_1016,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,974,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1017,PSIVISSIG0002_1017,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1504,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1018,PSIVISSIG0002_1018,55,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1069,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1019,PSIVISSIG0002_1019,43,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,176,0,PD,NA,PROTOCOL DEVIATION
PSIVISSIG0002,1020,PSIVISSIG0002_1020,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1577,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1021,PSIVISSIG0002_1021,82,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,558,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,1022,PSIVISSIG0002_1022,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1437,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1023,PSIVISSIG0002_1023,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,250,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1024,PSIVISSIG0002_1024,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,468,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1025,PSIVISSIG0002_1025,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1870,1,Ongoing on first next-line therapy,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1026,PSIVISSIG0002_1026,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1485,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1027,PSIVISSIG0002_1027,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1088,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1028,PSIVISSIG0002_1028,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,628,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1029,PSIVISSIG0002_1029,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,857,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1030,PSIVISSIG0002_1030,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,461,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1031,PSIVISSIG0002_1031,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1011,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1032,PSIVISSIG0002_1032,72,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,721,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1033,PSIVISSIG0002_1033,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1077,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1034,PSIVISSIG0002_1034,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1517,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1035,PSIVISSIG0002_1035,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1464,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1036,PSIVISSIG0002_1036,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,747,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1037,PSIVISSIG0002_1037,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,176,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1038,PSIVISSIG0002_1038,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,68,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1039,PSIVISSIG0002_1039,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,393,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1040,PSIVISSIG0002_1040,83,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,411,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1041,PSIVISSIG0002_1041,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,982,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1042,PSIVISSIG0002_1042,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,605,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1043,PSIVISSIG0002_1043,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1420,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1044,PSIVISSIG0002_1044,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,539,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1045,PSIVISSIG0002_1045,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,66,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1046,PSIVISSIG0002_1046,55,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,697,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1047,PSIVISSIG0002_1047,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,597,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1048,PSIVISSIG0002_1048,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,900,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1049,PSIVISSIG0002_1049,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,347,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1050,PSIVISSIG0002_1050,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,397,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1051,PSIVISSIG0002_1051,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,894,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1052,PSIVISSIG0002_1052,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,768,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1053,PSIVISSIG0002_1053,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,799,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1054,PSIVISSIG0002_1054,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,630,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1055,PSIVISSIG0002_1055,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,411,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1056,PSIVISSIG0002_1056,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,459,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1057,PSIVISSIG0002_1057,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,65,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1058,PSIVISSIG0002_1058,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1155,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1059,PSIVISSIG0002_1059,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,162,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1060,PSIVISSIG0002_1060,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,299,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1061,PSIVISSIG0002_1061,62,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,245,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1062,PSIVISSIG0002_1062,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1184,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1063,PSIVISSIG0002_1063,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,545,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1064,PSIVISSIG0002_1064,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1350,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1065,PSIVISSIG0002_1065,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,737,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1066,PSIVISSIG0002_1066,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,244,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1067,PSIVISSIG0002_1067,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1381,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1068,PSIVISSIG0002_1068,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,445,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1069,PSIVISSIG0002_1069,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,667,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1070,PSIVISSIG0002_1070,73,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,708,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1071,PSIVISSIG0002_1071,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,745,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1072,PSIVISSIG0002_1072,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,424,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1073,PSIVISSIG0002_1073,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,619,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1074,PSIVISSIG0002_1074,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1099,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1075,PSIVISSIG0002_1075,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1797,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1076,PSIVISSIG0002_1076,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,239,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1077,PSIVISSIG0002_1077,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,784,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,1078,PSIVISSIG0002_1078,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,753,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1079,PSIVISSIG0002_1079,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,615,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1080,PSIVISSIG0002_1080,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1524,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1081,PSIVISSIG0002_1081,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,866,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1082,PSIVISSIG0002_1082,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,860,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1083,PSIVISSIG0002_1083,65,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,199,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1084,PSIVISSIG0002_1084,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1101,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1085,PSIVISSIG0002_1085,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,303,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1086,PSIVISSIG0002_1086,62,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,451,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1087,PSIVISSIG0002_1087,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,491,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1088,PSIVISSIG0002_1088,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1126,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1089,PSIVISSIG0002_1089,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,796,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1090,PSIVISSIG0002_1090,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,800,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1091,PSIVISSIG0002_1091,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,522,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1092,PSIVISSIG0002_1092,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,801,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1093,PSIVISSIG0002_1093,77,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,467,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1094,PSIVISSIG0002_1094,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,802,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1095,PSIVISSIG0002_1095,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,982,0,PD,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1096,PSIVISSIG0002_1096,66,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,397,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1097,PSIVISSIG0002_1097,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1163,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1098,PSIVISSIG0002_1098,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1088,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1099,PSIVISSIG0002_1099,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1083,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1100,PSIVISSIG0002_1100,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1417,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1101,PSIVISSIG0002_1101,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,712,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1102,PSIVISSIG0002_1102,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,521,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1103,PSIVISSIG0002_1103,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,290,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1104,PSIVISSIG0002_1104,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,838,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1105,PSIVISSIG0002_1105,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,321,0,PD,NA,DEATH
PSIVISSIG0002,1106,PSIVISSIG0002_1106,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,401,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1107,PSIVISSIG0002_1107,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1304,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1108,PSIVISSIG0002_1108,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,575,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1109,PSIVISSIG0002_1109,53,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,583,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1110,PSIVISSIG0002_1110,71,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,242,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1111,PSIVISSIG0002_1111,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,400,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1112,PSIVISSIG0002_1112,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,255,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1113,PSIVISSIG0002_1113,69,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,288,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1114,PSIVISSIG0002_1114,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,270,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1115,PSIVISSIG0002_1115,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,466,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1116,PSIVISSIG0002_1116,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,341,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1117,PSIVISSIG0002_1117,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,614,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1118,PSIVISSIG0002_1118,84,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,889,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1119,PSIVISSIG0002_1119,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,750,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1120,PSIVISSIG0002_1120,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1478,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1121,PSIVISSIG0002_1121,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,403,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1122,PSIVISSIG0002_1122,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,519,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1123,PSIVISSIG0002_1123,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,735,0,Death,NA,DEATH
PSIVISSIG0002,1124,PSIVISSIG0002_1124,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1363,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1125,PSIVISSIG0002_1125,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1782,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1126,PSIVISSIG0002_1126,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,895,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1127,PSIVISSIG0002_1127,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,543,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1128,PSIVISSIG0002_1128,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,501,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1129,PSIVISSIG0002_1129,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1937,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1130,PSIVISSIG0002_1130,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1017,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1131,PSIVISSIG0002_1131,64,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1317,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1132,PSIVISSIG0002_1132,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1417,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1133,PSIVISSIG0002_1133,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,243,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1134,PSIVISSIG0002_1134,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,400,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1135,PSIVISSIG0002_1135,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1084,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1136,PSIVISSIG0002_1136,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1194,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1137,PSIVISSIG0002_1137,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,711,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1138,PSIVISSIG0002_1138,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,255,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1139,PSIVISSIG0002_1139,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,375,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1140,PSIVISSIG0002_1140,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,133,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1141,PSIVISSIG0002_1141,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,429,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1142,PSIVISSIG0002_1142,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,892,0,Death,NA,DEATH
PSIVISSIG0002,1143,PSIVISSIG0002_1143,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1085,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1144,PSIVISSIG0002_1144,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,420,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1145,PSIVISSIG0002_1145,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,888,0,Death,NA,DEATH
PSIVISSIG0002,1146,PSIVISSIG0002_1146,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,550,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1147,PSIVISSIG0002_1147,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,129,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1148,PSIVISSIG0002_1148,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,311,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1149,PSIVISSIG0002_1149,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,795,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1150,PSIVISSIG0002_1150,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,676,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1151,PSIVISSIG0002_1151,70,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,414,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1152,PSIVISSIG0002_1152,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,137,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1153,PSIVISSIG0002_1153,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,858,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1154,PSIVISSIG0002_1154,62,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,129,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1155,PSIVISSIG0002_1155,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1420,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1156,PSIVISSIG0002_1156,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,745,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1157,PSIVISSIG0002_1157,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,647,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1158,PSIVISSIG0002_1158,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1094,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1159,PSIVISSIG0002_1159,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,250,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1160,PSIVISSIG0002_1160,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,507,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1161,PSIVISSIG0002_1161,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,468,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1162,PSIVISSIG0002_1162,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1137,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1163,PSIVISSIG0002_1163,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,101,0,Death,NA,DEATH
PSIVISSIG0002,1164,PSIVISSIG0002_1164,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1195,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1165,PSIVISSIG0002_1165,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,615,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1166,PSIVISSIG0002_1166,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,796,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1167,PSIVISSIG0002_1167,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,479,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1168,PSIVISSIG0002_1168,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,436,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1169,PSIVISSIG0002_1169,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,527,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1170,PSIVISSIG0002_1170,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1788,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1171,PSIVISSIG0002_1171,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,608,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1172,PSIVISSIG0002_1172,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1484,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1173,PSIVISSIG0002_1173,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,434,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1174,PSIVISSIG0002_1174,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,124,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1175,PSIVISSIG0002_1175,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1062,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1176,PSIVISSIG0002_1176,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1165,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1177,PSIVISSIG0002_1177,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,695,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1178,PSIVISSIG0002_1178,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,442,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1179,PSIVISSIG0002_1179,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1179,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1180,PSIVISSIG0002_1180,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,594,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1181,PSIVISSIG0002_1181,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1476,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1182,PSIVISSIG0002_1182,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,427,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1183,PSIVISSIG0002_1183,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1057,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1184,PSIVISSIG0002_1184,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,913,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1185,PSIVISSIG0002_1185,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,471,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1186,PSIVISSIG0002_1186,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,384,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1187,PSIVISSIG0002_1187,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,512,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1188,PSIVISSIG0002_1188,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1243,0,Death,NA,DEATH
PSIVISSIG0002,1189,PSIVISSIG0002_1189,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,420,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1190,PSIVISSIG0002_1190,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,293,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1191,PSIVISSIG0002_1191,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,785,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1192,PSIVISSIG0002_1192,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,786,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1193,PSIVISSIG0002_1193,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1093,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1194,PSIVISSIG0002_1194,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,514,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1195,PSIVISSIG0002_1195,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,473,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1196,PSIVISSIG0002_1196,62,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,132,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1197,PSIVISSIG0002_1197,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1159,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1198,PSIVISSIG0002_1198,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,319,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1199,PSIVISSIG0002_1199,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,847,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1200,PSIVISSIG0002_1200,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,434,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1201,PSIVISSIG0002_1201,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1169,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1202,PSIVISSIG0002_1202,55,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,706,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1203,PSIVISSIG0002_1203,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,238,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1204,PSIVISSIG0002_1204,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1037,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1205,PSIVISSIG0002_1205,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,662,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1206,PSIVISSIG0002_1206,52,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,241,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1207,PSIVISSIG0002_1207,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,519,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1208,PSIVISSIG0002_1208,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,508,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1209,PSIVISSIG0002_1209,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,629,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1210,PSIVISSIG0002_1210,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,408,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1211,PSIVISSIG0002_1211,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,511,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1212,PSIVISSIG0002_1212,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,877,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1213,PSIVISSIG0002_1213,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1513,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1214,PSIVISSIG0002_1214,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1187,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1215,PSIVISSIG0002_1215,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,450,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1216,PSIVISSIG0002_1216,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,428,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1217,PSIVISSIG0002_1217,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1298,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1218,PSIVISSIG0002_1218,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,871,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1219,PSIVISSIG0002_1219,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1710,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1220,PSIVISSIG0002_1220,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1350,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1221,PSIVISSIG0002_1221,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,734,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1222,PSIVISSIG0002_1222,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,602,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1223,PSIVISSIG0002_1223,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1292,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1224,PSIVISSIG0002_1224,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,905,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1225,PSIVISSIG0002_1225,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,265,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1226,PSIVISSIG0002_1226,81,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1028,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1227,PSIVISSIG0002_1227,46,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,263,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1228,PSIVISSIG0002_1228,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,445,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1229,PSIVISSIG0002_1229,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1173,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1230,PSIVISSIG0002_1230,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,372,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1231,PSIVISSIG0002_1231,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1020,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1232,PSIVISSIG0002_1232,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,344,0,Death,NA,DEATH
PSIVISSIG0002,1233,PSIVISSIG0002_1233,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,319,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1234,PSIVISSIG0002_1234,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,364,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1235,PSIVISSIG0002_1235,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,287,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1236,PSIVISSIG0002_1236,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1478,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1237,PSIVISSIG0002_1237,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1657,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1238,PSIVISSIG0002_1238,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1413,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1239,PSIVISSIG0002_1239,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1319,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1240,PSIVISSIG0002_1240,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,469,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1241,PSIVISSIG0002_1241,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,409,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1242,PSIVISSIG0002_1242,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1406,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1243,PSIVISSIG0002_1243,58,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,406,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1244,PSIVISSIG0002_1244,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1092,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1245,PSIVISSIG0002_1245,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,16,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1246,PSIVISSIG0002_1246,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,418,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1247,PSIVISSIG0002_1247,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,622,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1248,PSIVISSIG0002_1248,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1189,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1249,PSIVISSIG0002_1249,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,543,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1250,PSIVISSIG0002_1250,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1092,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1251,PSIVISSIG0002_1251,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,373,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1252,PSIVISSIG0002_1252,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,909,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1253,PSIVISSIG0002_1253,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,976,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1254,PSIVISSIG0002_1254,60,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,311,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1255,PSIVISSIG0002_1255,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1027,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1256,PSIVISSIG0002_1256,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1815,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1257,PSIVISSIG0002_1257,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,518,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1258,PSIVISSIG0002_1258,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1041,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1259,PSIVISSIG0002_1259,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,378,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1260,PSIVISSIG0002_1260,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,811,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1261,PSIVISSIG0002_1261,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,622,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1262,PSIVISSIG0002_1262,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1530,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1263,PSIVISSIG0002_1263,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1029,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1264,PSIVISSIG0002_1264,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,589,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1265,PSIVISSIG0002_1265,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,459,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1266,PSIVISSIG0002_1266,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,482,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1267,PSIVISSIG0002_1267,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,184,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1268,PSIVISSIG0002_1268,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,452,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1269,PSIVISSIG0002_1269,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,407,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1270,PSIVISSIG0002_1270,41,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,495,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1271,PSIVISSIG0002_1271,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,147,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1272,PSIVISSIG0002_1272,68,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,714,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1273,PSIVISSIG0002_1273,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1390,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1274,PSIVISSIG0002_1274,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1812,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1275,PSIVISSIG0002_1275,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1421,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1276,PSIVISSIG0002_1276,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,531,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1277,PSIVISSIG0002_1277,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1459,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1278,PSIVISSIG0002_1278,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,681,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1279,PSIVISSIG0002_1279,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,804,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1280,PSIVISSIG0002_1280,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,750,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1281,PSIVISSIG0002_1281,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1216,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1282,PSIVISSIG0002_1282,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,571,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1283,PSIVISSIG0002_1283,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,48,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1284,PSIVISSIG0002_1284,43,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,179,0,PD,NA,PROTOCOL DEVIATION
PSIVISSIG0002,1285,PSIVISSIG0002_1285,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,553,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1286,PSIVISSIG0002_1286,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,523,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1287,PSIVISSIG0002_1287,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1194,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1288,PSIVISSIG0002_1288,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1015,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1289,PSIVISSIG0002_1289,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,411,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1290,PSIVISSIG0002_1290,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,859,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1291,PSIVISSIG0002_1291,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,809,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1292,PSIVISSIG0002_1292,56,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,675,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1293,PSIVISSIG0002_1293,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,351,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1294,PSIVISSIG0002_1294,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,291,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1295,PSIVISSIG0002_1295,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,301,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1296,PSIVISSIG0002_1296,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1305,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1297,PSIVISSIG0002_1297,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,346,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1298,PSIVISSIG0002_1298,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,672,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1299,PSIVISSIG0002_1299,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,402,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1300,PSIVISSIG0002_1300,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,229,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1301,PSIVISSIG0002_1301,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1132,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1302,PSIVISSIG0002_1302,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,131,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1303,PSIVISSIG0002_1303,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1800,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1304,PSIVISSIG0002_1304,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,850,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1305,PSIVISSIG0002_1305,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,296,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1306,PSIVISSIG0002_1306,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,320,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1307,PSIVISSIG0002_1307,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,574,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1308,PSIVISSIG0002_1308,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,643,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1309,PSIVISSIG0002_1309,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,604,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1310,PSIVISSIG0002_1310,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,738,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1311,PSIVISSIG0002_1311,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,609,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1312,PSIVISSIG0002_1312,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,615,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1313,PSIVISSIG0002_1313,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,123,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1314,PSIVISSIG0002_1314,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,475,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1315,PSIVISSIG0002_1315,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,559,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1316,PSIVISSIG0002_1316,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,767,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1317,PSIVISSIG0002_1317,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,979,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1318,PSIVISSIG0002_1318,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1133,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1319,PSIVISSIG0002_1319,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,134,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1320,PSIVISSIG0002_1320,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,853,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1321,PSIVISSIG0002_1321,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1173,1,Second next-line therapy initiated,Censored at the end date of the next-line therapy,PROGRESSIVE DISEASE
PSIVISSIG0002,1322,PSIVISSIG0002_1322,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1505,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1323,PSIVISSIG0002_1323,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,744,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1324,PSIVISSIG0002_1324,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,408,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1325,PSIVISSIG0002_1325,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,915,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1326,PSIVISSIG0002_1326,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1027,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1327,PSIVISSIG0002_1327,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,31,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1328,PSIVISSIG0002_1328,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,289,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1329,PSIVISSIG0002_1329,61,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,613,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1330,PSIVISSIG0002_1330,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,757,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1331,PSIVISSIG0002_1331,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,807,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1332,PSIVISSIG0002_1332,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1089,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1333,PSIVISSIG0002_1333,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1018,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1334,PSIVISSIG0002_1334,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,681,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1335,PSIVISSIG0002_1335,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,571,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1336,PSIVISSIG0002_1336,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,261,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1337,PSIVISSIG0002_1337,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,791,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1338,PSIVISSIG0002_1338,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,911,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1339,PSIVISSIG0002_1339,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1183,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1340,PSIVISSIG0002_1340,32,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,238,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1341,PSIVISSIG0002_1341,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,480,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1342,PSIVISSIG0002_1342,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1290,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1343,PSIVISSIG0002_1343,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,710,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1344,PSIVISSIG0002_1344,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,564,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1345,PSIVISSIG0002_1345,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,571,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1346,PSIVISSIG0002_1346,35,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,655,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1347,PSIVISSIG0002_1347,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,364,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1348,PSIVISSIG0002_1348,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,397,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1349,PSIVISSIG0002_1349,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,252,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1350,PSIVISSIG0002_1350,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,855,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1351,PSIVISSIG0002_1351,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,897,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1352,PSIVISSIG0002_1352,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,332,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1353,PSIVISSIG0002_1353,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1302,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1354,PSIVISSIG0002_1354,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,117,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1355,PSIVISSIG0002_1355,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,301,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1356,PSIVISSIG0002_1356,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,146,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1357,PSIVISSIG0002_1357,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1325,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1358,PSIVISSIG0002_1358,84,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,890,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1359,PSIVISSIG0002_1359,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,728,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1360,PSIVISSIG0002_1360,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,313,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1361,PSIVISSIG0002_1361,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,912,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1362,PSIVISSIG0002_1362,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1448,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1363,PSIVISSIG0002_1363,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1011,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1364,PSIVISSIG0002_1364,66,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,408,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1365,PSIVISSIG0002_1365,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,347,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1366,PSIVISSIG0002_1366,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,761,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1367,PSIVISSIG0002_1367,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,631,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1368,PSIVISSIG0002_1368,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,330,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1369,PSIVISSIG0002_1369,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1164,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1370,PSIVISSIG0002_1370,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,590,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1371,PSIVISSIG0002_1371,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,249,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1372,PSIVISSIG0002_1372,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,739,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1373,PSIVISSIG0002_1373,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1209,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1374,PSIVISSIG0002_1374,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,682,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1375,PSIVISSIG0002_1375,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,647,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1376,PSIVISSIG0002_1376,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,796,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1377,PSIVISSIG0002_1377,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,859,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1378,PSIVISSIG0002_1378,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,852,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1379,PSIVISSIG0002_1379,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,776,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1380,PSIVISSIG0002_1380,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,554,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1381,PSIVISSIG0002_1381,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,275,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1382,PSIVISSIG0002_1382,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1025,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1383,PSIVISSIG0002_1383,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,863,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1384,PSIVISSIG0002_1384,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1060,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1385,PSIVISSIG0002_1385,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1084,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1386,PSIVISSIG0002_1386,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,302,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1387,PSIVISSIG0002_1387,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,525,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1388,PSIVISSIG0002_1388,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,850,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1389,PSIVISSIG0002_1389,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,235,0,Death,NA,DEATH
PSIVISSIG0002,1390,PSIVISSIG0002_1390,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,997,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1391,PSIVISSIG0002_1391,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1456,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1392,PSIVISSIG0002_1392,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,129,0,Death,NA,PROTOCOL DEVIATION
PSIVISSIG0002,1393,PSIVISSIG0002_1393,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,873,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1394,PSIVISSIG0002_1394,71,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,231,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1395,PSIVISSIG0002_1395,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1593,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1396,PSIVISSIG0002_1396,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,299,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1397,PSIVISSIG0002_1397,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,731,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1398,PSIVISSIG0002_1398,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,581,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1399,PSIVISSIG0002_1399,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,142,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1400,PSIVISSIG0002_1400,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,587,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1401,PSIVISSIG0002_1401,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,630,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1402,PSIVISSIG0002_1402,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,264,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1403,PSIVISSIG0002_1403,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1057,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1404,PSIVISSIG0002_1404,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,746,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1405,PSIVISSIG0002_1405,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1087,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1406,PSIVISSIG0002_1406,73,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,706,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1407,PSIVISSIG0002_1407,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,615,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1408,PSIVISSIG0002_1408,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,570,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1409,PSIVISSIG0002_1409,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,408,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1410,PSIVISSIG0002_1410,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1438,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1411,PSIVISSIG0002_1411,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,737,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1412,PSIVISSIG0002_1412,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,853,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1413,PSIVISSIG0002_1413,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,473,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1414,PSIVISSIG0002_1414,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1493,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1415,PSIVISSIG0002_1415,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,171,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1416,PSIVISSIG0002_1416,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1310,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1417,PSIVISSIG0002_1417,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,262,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1418,PSIVISSIG0002_1418,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1244,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1419,PSIVISSIG0002_1419,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,459,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1420,PSIVISSIG0002_1420,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,969,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1421,PSIVISSIG0002_1421,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,803,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1422,PSIVISSIG0002_1422,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,944,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1423,PSIVISSIG0002_1423,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,865,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1424,PSIVISSIG0002_1424,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,615,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1425,PSIVISSIG0002_1425,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,673,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1426,PSIVISSIG0002_1426,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,339,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1427,PSIVISSIG0002_1427,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,803,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1428,PSIVISSIG0002_1428,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,336,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1429,PSIVISSIG0002_1429,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,637,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1430,PSIVISSIG0002_1430,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,346,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1431,PSIVISSIG0002_1431,77,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,400,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1432,PSIVISSIG0002_1432,83,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,403,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1433,PSIVISSIG0002_1433,71,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,241,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1434,PSIVISSIG0002_1434,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,627,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1435,PSIVISSIG0002_1435,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,825,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1436,PSIVISSIG0002_1436,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1650,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1437,PSIVISSIG0002_1437,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1354,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1438,PSIVISSIG0002_1438,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,836,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1439,PSIVISSIG0002_1439,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,159,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1440,PSIVISSIG0002_1440,25,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,789,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1441,PSIVISSIG0002_1441,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,729,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1442,PSIVISSIG0002_1442,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,380,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1443,PSIVISSIG0002_1443,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,499,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1444,PSIVISSIG0002_1444,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,333,0,Death,NA,DEATH
PSIVISSIG0002,1445,PSIVISSIG0002_1445,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1046,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1446,PSIVISSIG0002_1446,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,683,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1447,PSIVISSIG0002_1447,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,558,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1448,PSIVISSIG0002_1448,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,345,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1449,PSIVISSIG0002_1449,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,441,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1450,PSIVISSIG0002_1450,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1310,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1451,PSIVISSIG0002_1451,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,864,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1452,PSIVISSIG0002_1452,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,95,0,Death,NA,DEATH
PSIVISSIG0002,1453,PSIVISSIG0002_1453,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1944,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1454,PSIVISSIG0002_1454,61,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,597,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1455,PSIVISSIG0002_1455,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,802,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1456,PSIVISSIG0002_1456,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,752,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1457,PSIVISSIG0002_1457,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,313,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1458,PSIVISSIG0002_1458,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,927,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1459,PSIVISSIG0002_1459,55,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,709,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1460,PSIVISSIG0002_1460,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1451,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1461,PSIVISSIG0002_1461,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,42,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1462,PSIVISSIG0002_1462,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,653,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1463,PSIVISSIG0002_1463,71,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,480,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1464,PSIVISSIG0002_1464,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,784,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1465,PSIVISSIG0002_1465,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1081,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1466,PSIVISSIG0002_1466,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,462,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1467,PSIVISSIG0002_1467,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,699,1,No next-line therapy initiated,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1468,PSIVISSIG0002_1468,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,913,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1469,PSIVISSIG0002_1469,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,202,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1470,PSIVISSIG0002_1470,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,106,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1471,PSIVISSIG0002_1471,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1405,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1472,PSIVISSIG0002_1472,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,105,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1473,PSIVISSIG0002_1473,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,851,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1474,PSIVISSIG0002_1474,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,708,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1475,PSIVISSIG0002_1475,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,273,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1476,PSIVISSIG0002_1476,39,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,408,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1477,PSIVISSIG0002_1477,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1422,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1478,PSIVISSIG0002_1478,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,898,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1479,PSIVISSIG0002_1479,89,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,531,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1480,PSIVISSIG0002_1480,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,294,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1481,PSIVISSIG0002_1481,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,321,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1482,PSIVISSIG0002_1482,56,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,691,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1483,PSIVISSIG0002_1483,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,271,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1484,PSIVISSIG0002_1484,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,227,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1485,PSIVISSIG0002_1485,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1354,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1486,PSIVISSIG0002_1486,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,434,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1487,PSIVISSIG0002_1487,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1654,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1488,PSIVISSIG0002_1488,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,227,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1489,PSIVISSIG0002_1489,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,383,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1490,PSIVISSIG0002_1490,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,189,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1491,PSIVISSIG0002_1491,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,902,0,Death,NA,DEATH
PSIVISSIG0002,1492,PSIVISSIG0002_1492,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,778,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1493,PSIVISSIG0002_1493,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,905,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1494,PSIVISSIG0002_1494,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,915,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1495,PSIVISSIG0002_1495,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,315,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1496,PSIVISSIG0002_1496,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,814,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1497,PSIVISSIG0002_1497,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,909,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1498,PSIVISSIG0002_1498,83,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,416,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1499,PSIVISSIG0002_1499,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1291,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1500,PSIVISSIG0002_1500,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1491,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1501,PSIVISSIG0002_1501,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,236,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1502,PSIVISSIG0002_1502,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,190,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1503,PSIVISSIG0002_1503,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,435,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1504,PSIVISSIG0002_1504,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,180,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1505,PSIVISSIG0002_1505,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1086,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1506,PSIVISSIG0002_1506,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,556,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1507,PSIVISSIG0002_1507,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,476,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1508,PSIVISSIG0002_1508,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,519,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1509,PSIVISSIG0002_1509,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,478,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1510,PSIVISSIG0002_1510,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,109,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1511,PSIVISSIG0002_1511,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,362,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1512,PSIVISSIG0002_1512,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,129,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1513,PSIVISSIG0002_1513,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,734,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1514,PSIVISSIG0002_1514,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,188,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1515,PSIVISSIG0002_1515,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,442,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1516,PSIVISSIG0002_1516,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,73,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1517,PSIVISSIG0002_1517,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1301,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1518,PSIVISSIG0002_1518,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,34,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1519,PSIVISSIG0002_1519,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,466,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1520,PSIVISSIG0002_1520,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,978,0,PD,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1521,PSIVISSIG0002_1521,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1236,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1522,PSIVISSIG0002_1522,62,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,451,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1523,PSIVISSIG0002_1523,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,456,1,Ongoing on first next-line therapy,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1524,PSIVISSIG0002_1524,56,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,692,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1525,PSIVISSIG0002_1525,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,599,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1526,PSIVISSIG0002_1526,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,34,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1527,PSIVISSIG0002_1527,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,149,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1528,PSIVISSIG0002_1528,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1529,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1529,PSIVISSIG0002_1529,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,698,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1530,PSIVISSIG0002_1530,57,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,577,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1531,PSIVISSIG0002_1531,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,648,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1532,PSIVISSIG0002_1532,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,854,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1533,PSIVISSIG0002_1533,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,812,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1534,PSIVISSIG0002_1534,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,593,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1535,PSIVISSIG0002_1535,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,349,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1536,PSIVISSIG0002_1536,65,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,188,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1537,PSIVISSIG0002_1537,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,125,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1538,PSIVISSIG0002_1538,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,790,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1539,PSIVISSIG0002_1539,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1813,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1540,PSIVISSIG0002_1540,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,677,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1541,PSIVISSIG0002_1541,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1177,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1542,PSIVISSIG0002_1542,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,630,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1543,PSIVISSIG0002_1543,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1588,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1544,PSIVISSIG0002_1544,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,798,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1545,PSIVISSIG0002_1545,88,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,350,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1546,PSIVISSIG0002_1546,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1091,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1547,PSIVISSIG0002_1547,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1696,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1548,PSIVISSIG0002_1548,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,150,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1549,PSIVISSIG0002_1549,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,69,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1550,PSIVISSIG0002_1550,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,756,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1551,PSIVISSIG0002_1551,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,781,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1552,PSIVISSIG0002_1552,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,677,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1553,PSIVISSIG0002_1553,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,297,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1554,PSIVISSIG0002_1554,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,348,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1555,PSIVISSIG0002_1555,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1171,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1556,PSIVISSIG0002_1556,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,983,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1557,PSIVISSIG0002_1557,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,344,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1558,PSIVISSIG0002_1558,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1142,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1559,PSIVISSIG0002_1559,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1062,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1560,PSIVISSIG0002_1560,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,389,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1561,PSIVISSIG0002_1561,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,462,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1562,PSIVISSIG0002_1562,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,269,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1563,PSIVISSIG0002_1563,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,294,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1564,PSIVISSIG0002_1564,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,606,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1565,PSIVISSIG0002_1565,71,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,242,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1566,PSIVISSIG0002_1566,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,672,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1567,PSIVISSIG0002_1567,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,627,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1568,PSIVISSIG0002_1568,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,131,0,Death,NA,PROTOCOL DEVIATION
PSIVISSIG0002,1569,PSIVISSIG0002_1569,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,279,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1570,PSIVISSIG0002_1570,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,603,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1571,PSIVISSIG0002_1571,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1441,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1572,PSIVISSIG0002_1572,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,69,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1573,PSIVISSIG0002_1573,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,589,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1574,PSIVISSIG0002_1574,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,150,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1575,PSIVISSIG0002_1575,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1042,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1576,PSIVISSIG0002_1576,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,118,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1577,PSIVISSIG0002_1577,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,831,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1578,PSIVISSIG0002_1578,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1357,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1579,PSIVISSIG0002_1579,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1134,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1580,PSIVISSIG0002_1580,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,429,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1581,PSIVISSIG0002_1581,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,378,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1582,PSIVISSIG0002_1582,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,114,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1583,PSIVISSIG0002_1583,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1299,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1584,PSIVISSIG0002_1584,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1357,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,1585,PSIVISSIG0002_1585,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,391,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1586,PSIVISSIG0002_1586,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,264,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1587,PSIVISSIG0002_1587,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1140,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1588,PSIVISSIG0002_1588,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,793,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1589,PSIVISSIG0002_1589,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,308,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1590,PSIVISSIG0002_1590,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1479,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1591,PSIVISSIG0002_1591,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,852,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1592,PSIVISSIG0002_1592,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,421,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1593,PSIVISSIG0002_1593,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,454,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1594,PSIVISSIG0002_1594,57,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,572,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1595,PSIVISSIG0002_1595,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,832,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1596,PSIVISSIG0002_1596,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,911,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1597,PSIVISSIG0002_1597,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,502,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1598,PSIVISSIG0002_1598,45,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,253,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1599,PSIVISSIG0002_1599,77,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,395,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1600,PSIVISSIG0002_1600,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,854,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1601,PSIVISSIG0002_1601,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,63,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1602,PSIVISSIG0002_1602,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1296,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1603,PSIVISSIG0002_1603,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,195,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1604,PSIVISSIG0002_1604,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,163,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1605,PSIVISSIG0002_1605,77,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,473,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1606,PSIVISSIG0002_1606,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,154,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1607,PSIVISSIG0002_1607,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,543,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1608,PSIVISSIG0002_1608,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,612,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1609,PSIVISSIG0002_1609,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,397,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1610,PSIVISSIG0002_1610,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,855,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1611,PSIVISSIG0002_1611,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1296,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1612,PSIVISSIG0002_1612,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,633,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1613,PSIVISSIG0002_1613,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,592,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1614,PSIVISSIG0002_1614,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,390,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1615,PSIVISSIG0002_1615,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,465,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1616,PSIVISSIG0002_1616,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,405,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1617,PSIVISSIG0002_1617,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,131,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1618,PSIVISSIG0002_1618,65,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,133,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1619,PSIVISSIG0002_1619,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,577,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1620,PSIVISSIG0002_1620,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,475,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1621,PSIVISSIG0002_1621,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,474,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1622,PSIVISSIG0002_1622,41,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,602,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1623,PSIVISSIG0002_1623,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,781,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1624,PSIVISSIG0002_1624,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,921,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1625,PSIVISSIG0002_1625,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,744,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1626,PSIVISSIG0002_1626,71,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,238,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1627,PSIVISSIG0002_1627,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,241,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1628,PSIVISSIG0002_1628,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,800,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1629,PSIVISSIG0002_1629,43,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,179,0,PD,NA,PROTOCOL DEVIATION
PSIVISSIG0002,1630,PSIVISSIG0002_1630,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,515,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1631,PSIVISSIG0002_1631,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,566,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1632,PSIVISSIG0002_1632,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,259,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1633,PSIVISSIG0002_1633,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,858,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1634,PSIVISSIG0002_1634,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,553,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1635,PSIVISSIG0002_1635,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1005,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1636,PSIVISSIG0002_1636,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,729,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1637,PSIVISSIG0002_1637,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,313,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1638,PSIVISSIG0002_1638,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1347,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1639,PSIVISSIG0002_1639,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,370,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1640,PSIVISSIG0002_1640,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,633,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1641,PSIVISSIG0002_1641,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,737,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1642,PSIVISSIG0002_1642,72,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,731,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1643,PSIVISSIG0002_1643,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,829,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1644,PSIVISSIG0002_1644,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,443,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1645,PSIVISSIG0002_1645,69,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,297,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1646,PSIVISSIG0002_1646,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,522,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1647,PSIVISSIG0002_1647,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,541,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1648,PSIVISSIG0002_1648,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1022,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1649,PSIVISSIG0002_1649,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,388,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1650,PSIVISSIG0002_1650,71,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,239,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1651,PSIVISSIG0002_1651,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,707,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1652,PSIVISSIG0002_1652,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,935,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,1653,PSIVISSIG0002_1653,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,230,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1654,PSIVISSIG0002_1654,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,30,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1655,PSIVISSIG0002_1655,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1313,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1656,PSIVISSIG0002_1656,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,867,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1657,PSIVISSIG0002_1657,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,132,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1658,PSIVISSIG0002_1658,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,418,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1659,PSIVISSIG0002_1659,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,573,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1660,PSIVISSIG0002_1660,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,361,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1661,PSIVISSIG0002_1661,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1082,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1662,PSIVISSIG0002_1662,81,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1020,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1663,PSIVISSIG0002_1663,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,605,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1664,PSIVISSIG0002_1664,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1374,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1665,PSIVISSIG0002_1665,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1088,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1666,PSIVISSIG0002_1666,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,927,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1667,PSIVISSIG0002_1667,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,129,0,Death,NA,PROTOCOL DEVIATION
PSIVISSIG0002,1668,PSIVISSIG0002_1668,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,249,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1669,PSIVISSIG0002_1669,71,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,233,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1670,PSIVISSIG0002_1670,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,647,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1671,PSIVISSIG0002_1671,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,238,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1672,PSIVISSIG0002_1672,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,27,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1673,PSIVISSIG0002_1673,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,976,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1674,PSIVISSIG0002_1674,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,183,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1675,PSIVISSIG0002_1675,83,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,402,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1676,PSIVISSIG0002_1676,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1223,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1677,PSIVISSIG0002_1677,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,508,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1678,PSIVISSIG0002_1678,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1300,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1679,PSIVISSIG0002_1679,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,708,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1680,PSIVISSIG0002_1680,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,467,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1681,PSIVISSIG0002_1681,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,425,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1682,PSIVISSIG0002_1682,51,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1086,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1683,PSIVISSIG0002_1683,84,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,131,0,Death,NA,DEATH
PSIVISSIG0002,1684,PSIVISSIG0002_1684,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,362,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1685,PSIVISSIG0002_1685,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,760,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1686,PSIVISSIG0002_1686,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,857,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1687,PSIVISSIG0002_1687,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,618,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1688,PSIVISSIG0002_1688,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,691,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1689,PSIVISSIG0002_1689,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,171,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1690,PSIVISSIG0002_1690,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1449,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1691,PSIVISSIG0002_1691,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,240,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1692,PSIVISSIG0002_1692,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1790,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1693,PSIVISSIG0002_1693,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,150,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1694,PSIVISSIG0002_1694,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,693,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1695,PSIVISSIG0002_1695,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,879,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1696,PSIVISSIG0002_1696,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,453,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1697,PSIVISSIG0002_1697,53,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,591,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1698,PSIVISSIG0002_1698,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,343,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1699,PSIVISSIG0002_1699,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,523,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1700,PSIVISSIG0002_1700,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,503,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1701,PSIVISSIG0002_1701,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,901,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1702,PSIVISSIG0002_1702,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,225,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1703,PSIVISSIG0002_1703,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,596,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1704,PSIVISSIG0002_1704,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,642,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1705,PSIVISSIG0002_1705,60,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,903,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1706,PSIVISSIG0002_1706,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,857,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1707,PSIVISSIG0002_1707,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,461,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1708,PSIVISSIG0002_1708,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,319,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1709,PSIVISSIG0002_1709,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1504,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1710,PSIVISSIG0002_1710,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,919,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1711,PSIVISSIG0002_1711,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1187,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1712,PSIVISSIG0002_1712,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1390,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1713,PSIVISSIG0002_1713,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,455,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1714,PSIVISSIG0002_1714,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,473,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1715,PSIVISSIG0002_1715,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,843,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1716,PSIVISSIG0002_1716,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,288,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1717,PSIVISSIG0002_1717,53,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,592,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1718,PSIVISSIG0002_1718,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1501,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1719,PSIVISSIG0002_1719,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,572,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1720,PSIVISSIG0002_1720,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,713,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1721,PSIVISSIG0002_1721,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1406,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1722,PSIVISSIG0002_1722,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,690,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1723,PSIVISSIG0002_1723,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,634,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1724,PSIVISSIG0002_1724,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1353,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1725,PSIVISSIG0002_1725,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,236,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1726,PSIVISSIG0002_1726,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,156,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1727,PSIVISSIG0002_1727,81,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1013,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1728,PSIVISSIG0002_1728,69,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,579,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1729,PSIVISSIG0002_1729,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,657,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1730,PSIVISSIG0002_1730,32,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,231,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1731,PSIVISSIG0002_1731,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,343,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1732,PSIVISSIG0002_1732,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1713,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1733,PSIVISSIG0002_1733,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,807,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1734,PSIVISSIG0002_1734,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,160,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1735,PSIVISSIG0002_1735,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,857,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1736,PSIVISSIG0002_1736,42,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,199,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1737,PSIVISSIG0002_1737,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,397,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1738,PSIVISSIG0002_1738,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1407,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1739,PSIVISSIG0002_1739,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1210,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1740,PSIVISSIG0002_1740,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1304,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1741,PSIVISSIG0002_1741,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1365,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1742,PSIVISSIG0002_1742,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1168,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1743,PSIVISSIG0002_1743,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1168,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1744,PSIVISSIG0002_1744,55,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,700,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1745,PSIVISSIG0002_1745,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1359,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1746,PSIVISSIG0002_1746,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,743,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1747,PSIVISSIG0002_1747,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,332,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1748,PSIVISSIG0002_1748,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,777,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1749,PSIVISSIG0002_1749,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,744,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1750,PSIVISSIG0002_1750,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,456,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1751,PSIVISSIG0002_1751,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,246,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1752,PSIVISSIG0002_1752,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1007,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1753,PSIVISSIG0002_1753,82,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,547,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,1754,PSIVISSIG0002_1754,77,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,457,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1755,PSIVISSIG0002_1755,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,622,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1756,PSIVISSIG0002_1756,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,986,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1757,PSIVISSIG0002_1757,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,993,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1758,PSIVISSIG0002_1758,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,665,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1759,PSIVISSIG0002_1759,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,343,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1760,PSIVISSIG0002_1760,67,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,911,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1761,PSIVISSIG0002_1761,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,303,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1762,PSIVISSIG0002_1762,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,591,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1763,PSIVISSIG0002_1763,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,996,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1764,PSIVISSIG0002_1764,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,544,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1765,PSIVISSIG0002_1765,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,179,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1766,PSIVISSIG0002_1766,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,142,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1767,PSIVISSIG0002_1767,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,223,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1768,PSIVISSIG0002_1768,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,301,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1769,PSIVISSIG0002_1769,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,675,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1770,PSIVISSIG0002_1770,57,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,576,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1771,PSIVISSIG0002_1771,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,591,1,Second next-line therapy initiated,Censored at the end date of the next-line therapy,PROGRESSIVE DISEASE
PSIVISSIG0002,1772,PSIVISSIG0002_1772,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,179,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1773,PSIVISSIG0002_1773,65,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,244,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1774,PSIVISSIG0002_1774,48,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,688,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1775,PSIVISSIG0002_1775,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,432,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1776,PSIVISSIG0002_1776,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,151,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1777,PSIVISSIG0002_1777,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,753,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1778,PSIVISSIG0002_1778,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,568,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1779,PSIVISSIG0002_1779,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,862,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1780,PSIVISSIG0002_1780,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,577,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1781,PSIVISSIG0002_1781,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,665,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1782,PSIVISSIG0002_1782,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,37,0,Death,NA,DEATH
PSIVISSIG0002,1783,PSIVISSIG0002_1783,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,610,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1784,PSIVISSIG0002_1784,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,539,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1785,PSIVISSIG0002_1785,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1005,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1786,PSIVISSIG0002_1786,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,114,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1787,PSIVISSIG0002_1787,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,900,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1788,PSIVISSIG0002_1788,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,478,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1789,PSIVISSIG0002_1789,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,296,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1790,PSIVISSIG0002_1790,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,231,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1791,PSIVISSIG0002_1791,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,552,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1792,PSIVISSIG0002_1792,81,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1017,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1793,PSIVISSIG0002_1793,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1082,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1794,PSIVISSIG0002_1794,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1363,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1795,PSIVISSIG0002_1795,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,132,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1796,PSIVISSIG0002_1796,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,286,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1797,PSIVISSIG0002_1797,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,366,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1798,PSIVISSIG0002_1798,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,629,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1799,PSIVISSIG0002_1799,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,288,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1800,PSIVISSIG0002_1800,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,541,1,Lost to follow-up,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1801,PSIVISSIG0002_1801,82,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,283,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1802,PSIVISSIG0002_1802,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1138,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1803,PSIVISSIG0002_1803,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1087,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1804,PSIVISSIG0002_1804,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,747,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1805,PSIVISSIG0002_1805,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,289,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1806,PSIVISSIG0002_1806,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1014,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1807,PSIVISSIG0002_1807,66,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,396,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1808,PSIVISSIG0002_1808,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,227,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1809,PSIVISSIG0002_1809,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1186,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1810,PSIVISSIG0002_1810,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,528,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1811,PSIVISSIG0002_1811,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1036,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1812,PSIVISSIG0002_1812,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1111,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1813,PSIVISSIG0002_1813,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,777,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1814,PSIVISSIG0002_1814,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,129,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1815,PSIVISSIG0002_1815,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,578,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1816,PSIVISSIG0002_1816,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,665,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1817,PSIVISSIG0002_1817,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,485,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1818,PSIVISSIG0002_1818,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1079,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1819,PSIVISSIG0002_1819,81,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,239,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1820,PSIVISSIG0002_1820,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1814,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1821,PSIVISSIG0002_1821,69,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,581,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1822,PSIVISSIG0002_1822,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,691,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1823,PSIVISSIG0002_1823,85,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,37,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1824,PSIVISSIG0002_1824,64,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1315,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1825,PSIVISSIG0002_1825,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,687,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1826,PSIVISSIG0002_1826,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,225,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1827,PSIVISSIG0002_1827,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,549,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1828,PSIVISSIG0002_1828,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,701,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1829,PSIVISSIG0002_1829,47,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,192,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1830,PSIVISSIG0002_1830,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,189,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1831,PSIVISSIG0002_1831,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1076,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1832,PSIVISSIG0002_1832,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,665,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1833,PSIVISSIG0002_1833,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,285,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1834,PSIVISSIG0002_1834,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,228,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1835,PSIVISSIG0002_1835,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,623,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1836,PSIVISSIG0002_1836,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1163,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1837,PSIVISSIG0002_1837,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1477,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1838,PSIVISSIG0002_1838,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,911,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1839,PSIVISSIG0002_1839,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1095,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1840,PSIVISSIG0002_1840,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,623,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1841,PSIVISSIG0002_1841,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1462,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1842,PSIVISSIG0002_1842,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,584,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1843,PSIVISSIG0002_1843,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,673,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1844,PSIVISSIG0002_1844,71,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,235,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1845,PSIVISSIG0002_1845,25,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,802,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1846,PSIVISSIG0002_1846,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,790,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1847,PSIVISSIG0002_1847,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1413,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1848,PSIVISSIG0002_1848,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,731,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1849,PSIVISSIG0002_1849,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,138,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1850,PSIVISSIG0002_1850,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,405,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1851,PSIVISSIG0002_1851,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,578,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1852,PSIVISSIG0002_1852,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,284,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1853,PSIVISSIG0002_1853,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1103,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1854,PSIVISSIG0002_1854,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,435,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1855,PSIVISSIG0002_1855,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,532,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1856,PSIVISSIG0002_1856,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,423,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1857,PSIVISSIG0002_1857,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,747,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1858,PSIVISSIG0002_1858,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,801,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,1859,PSIVISSIG0002_1859,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,471,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1860,PSIVISSIG0002_1860,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,543,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1861,PSIVISSIG0002_1861,40,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,187,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1862,PSIVISSIG0002_1862,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1935,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1863,PSIVISSIG0002_1863,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,424,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1864,PSIVISSIG0002_1864,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,628,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1865,PSIVISSIG0002_1865,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1012,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1866,PSIVISSIG0002_1866,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,309,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1867,PSIVISSIG0002_1867,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,335,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1868,PSIVISSIG0002_1868,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,235,0,Death,NA,DEATH
PSIVISSIG0002,1869,PSIVISSIG0002_1869,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,130,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1870,PSIVISSIG0002_1870,62,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,259,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1871,PSIVISSIG0002_1871,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,514,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1872,PSIVISSIG0002_1872,84,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,886,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1873,PSIVISSIG0002_1873,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,752,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1874,PSIVISSIG0002_1874,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,502,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1875,PSIVISSIG0002_1875,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,694,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1876,PSIVISSIG0002_1876,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,316,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1877,PSIVISSIG0002_1877,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1047,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1878,PSIVISSIG0002_1878,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,905,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1879,PSIVISSIG0002_1879,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1183,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1880,PSIVISSIG0002_1880,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1238,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1881,PSIVISSIG0002_1881,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1247,0,Death,NA,DEATH
PSIVISSIG0002,1882,PSIVISSIG0002_1882,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1130,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1883,PSIVISSIG0002_1883,35,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,663,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1884,PSIVISSIG0002_1884,65,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,246,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1885,PSIVISSIG0002_1885,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,585,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1886,PSIVISSIG0002_1886,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,296,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1887,PSIVISSIG0002_1887,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,865,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1888,PSIVISSIG0002_1888,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,262,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1889,PSIVISSIG0002_1889,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,395,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,1890,PSIVISSIG0002_1890,80,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,271,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1891,PSIVISSIG0002_1891,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1318,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1892,PSIVISSIG0002_1892,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,541,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1893,PSIVISSIG0002_1893,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,936,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1894,PSIVISSIG0002_1894,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1182,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1895,PSIVISSIG0002_1895,56,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,695,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1896,PSIVISSIG0002_1896,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,395,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1897,PSIVISSIG0002_1897,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,571,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1898,PSIVISSIG0002_1898,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1155,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1899,PSIVISSIG0002_1899,84,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,886,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1900,PSIVISSIG0002_1900,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,543,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1901,PSIVISSIG0002_1901,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1081,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1902,PSIVISSIG0002_1902,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,303,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1903,PSIVISSIG0002_1903,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1926,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1904,PSIVISSIG0002_1904,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,912,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1905,PSIVISSIG0002_1905,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1353,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1906,PSIVISSIG0002_1906,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,173,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1907,PSIVISSIG0002_1907,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,797,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1908,PSIVISSIG0002_1908,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,900,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1909,PSIVISSIG0002_1909,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,547,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1910,PSIVISSIG0002_1910,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1301,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1911,PSIVISSIG0002_1911,45,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1809,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1912,PSIVISSIG0002_1912,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1164,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1913,PSIVISSIG0002_1913,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1532,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1914,PSIVISSIG0002_1914,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1091,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1915,PSIVISSIG0002_1915,40,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,175,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1916,PSIVISSIG0002_1916,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,356,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1917,PSIVISSIG0002_1917,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,673,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1918,PSIVISSIG0002_1918,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1017,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1919,PSIVISSIG0002_1919,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,441,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1920,PSIVISSIG0002_1920,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,992,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1921,PSIVISSIG0002_1921,56,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,69,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,1922,PSIVISSIG0002_1922,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1033,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1923,PSIVISSIG0002_1923,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,393,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1924,PSIVISSIG0002_1924,67,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,922,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1925,PSIVISSIG0002_1925,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,581,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1926,PSIVISSIG0002_1926,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1184,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1927,PSIVISSIG0002_1927,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1093,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1928,PSIVISSIG0002_1928,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,905,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1929,PSIVISSIG0002_1929,79,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1243,0,Death,NA,DEATH
PSIVISSIG0002,1930,PSIVISSIG0002_1930,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1143,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1931,PSIVISSIG0002_1931,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1210,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1932,PSIVISSIG0002_1932,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,779,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1933,PSIVISSIG0002_1933,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,904,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1934,PSIVISSIG0002_1934,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,523,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1935,PSIVISSIG0002_1935,84,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,139,0,Death,NA,DEATH
PSIVISSIG0002,1936,PSIVISSIG0002_1936,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,747,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1937,PSIVISSIG0002_1937,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,193,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1938,PSIVISSIG0002_1938,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,361,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1939,PSIVISSIG0002_1939,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,833,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1940,PSIVISSIG0002_1940,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,40,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1941,PSIVISSIG0002_1941,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1083,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1942,PSIVISSIG0002_1942,85,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,33,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1943,PSIVISSIG0002_1943,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,357,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1944,PSIVISSIG0002_1944,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,242,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1945,PSIVISSIG0002_1945,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1490,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1946,PSIVISSIG0002_1946,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,219,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1947,PSIVISSIG0002_1947,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,911,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1948,PSIVISSIG0002_1948,49,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,342,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1949,PSIVISSIG0002_1949,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,799,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1950,PSIVISSIG0002_1950,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1029,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1951,PSIVISSIG0002_1951,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,572,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1952,PSIVISSIG0002_1952,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,289,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1953,PSIVISSIG0002_1953,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,610,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1954,PSIVISSIG0002_1954,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,181,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1955,PSIVISSIG0002_1955,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,736,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1956,PSIVISSIG0002_1956,78,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,473,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1957,PSIVISSIG0002_1957,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,350,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1958,PSIVISSIG0002_1958,78,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,636,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1959,PSIVISSIG0002_1959,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,240,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1960,PSIVISSIG0002_1960,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,177,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1961,PSIVISSIG0002_1961,68,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,711,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1962,PSIVISSIG0002_1962,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,255,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1963,PSIVISSIG0002_1963,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,905,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1964,PSIVISSIG0002_1964,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,910,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1965,PSIVISSIG0002_1965,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,605,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1966,PSIVISSIG0002_1966,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,789,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1967,PSIVISSIG0002_1967,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1544,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1968,PSIVISSIG0002_1968,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,613,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1969,PSIVISSIG0002_1969,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1371,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1970,PSIVISSIG0002_1970,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,310,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1971,PSIVISSIG0002_1971,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1014,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1972,PSIVISSIG0002_1972,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,731,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1973,PSIVISSIG0002_1973,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,703,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1974,PSIVISSIG0002_1974,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1450,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1975,PSIVISSIG0002_1975,41,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,511,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1976,PSIVISSIG0002_1976,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,800,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1977,PSIVISSIG0002_1977,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,470,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1978,PSIVISSIG0002_1978,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,973,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1979,PSIVISSIG0002_1979,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,305,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1980,PSIVISSIG0002_1980,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,555,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1981,PSIVISSIG0002_1981,75,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,560,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1982,PSIVISSIG0002_1982,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,599,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1983,PSIVISSIG0002_1983,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,296,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1984,PSIVISSIG0002_1984,38,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,240,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1985,PSIVISSIG0002_1985,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,59,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1986,PSIVISSIG0002_1986,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1287,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1987,PSIVISSIG0002_1987,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,767,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1988,PSIVISSIG0002_1988,53,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,494,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1989,PSIVISSIG0002_1989,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,485,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1990,PSIVISSIG0002_1990,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1360,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,1991,PSIVISSIG0002_1991,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,273,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,1992,PSIVISSIG0002_1992,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,286,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,1993,PSIVISSIG0002_1993,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1053,1,Ongoing on first next-line therapy,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1994,PSIVISSIG0002_1994,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,913,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1995,PSIVISSIG0002_1995,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,839,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1996,PSIVISSIG0002_1996,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1082,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1997,PSIVISSIG0002_1997,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,777,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1998,PSIVISSIG0002_1998,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1028,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,1999,PSIVISSIG0002_1999,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,194,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2000,PSIVISSIG0002_2000,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,596,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2001,PSIVISSIG0002_2001,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1008,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2002,PSIVISSIG0002_2002,52,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,497,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2003,PSIVISSIG0002_2003,71,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,479,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2004,PSIVISSIG0002_2004,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1819,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2005,PSIVISSIG0002_2005,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,268,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2006,PSIVISSIG0002_2006,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,244,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2007,PSIVISSIG0002_2007,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,345,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2008,PSIVISSIG0002_2008,56,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,211,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2009,PSIVISSIG0002_2009,48,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1037,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2010,PSIVISSIG0002_2010,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,647,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,2011,PSIVISSIG0002_2011,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,422,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2012,PSIVISSIG0002_2012,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1183,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2013,PSIVISSIG0002_2013,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,367,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2014,PSIVISSIG0002_2014,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,847,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2015,PSIVISSIG0002_2015,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,693,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2016,PSIVISSIG0002_2016,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,553,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2017,PSIVISSIG0002_2017,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,244,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,2018,PSIVISSIG0002_2018,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1173,0,Death,NA,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2019,PSIVISSIG0002_2019,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,774,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2020,PSIVISSIG0002_2020,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1502,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2021,PSIVISSIG0002_2021,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1738,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2022,PSIVISSIG0002_2022,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1169,1,Second next-line therapy initiated,Censored at the end date of the next-line therapy,PROGRESSIVE DISEASE
PSIVISSIG0002,2023,PSIVISSIG0002_2023,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,565,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2024,PSIVISSIG0002_2024,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,980,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2025,PSIVISSIG0002_2025,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,32,0,Death,NA,DEATH
PSIVISSIG0002,2026,PSIVISSIG0002_2026,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,519,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2027,PSIVISSIG0002_2027,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,149,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2028,PSIVISSIG0002_2028,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,947,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,2029,PSIVISSIG0002_2029,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1412,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2030,PSIVISSIG0002_2030,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,442,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2031,PSIVISSIG0002_2031,39,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,404,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2032,PSIVISSIG0002_2032,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1144,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2033,PSIVISSIG0002_2033,73,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,652,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,2034,PSIVISSIG0002_2034,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,256,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2035,PSIVISSIG0002_2035,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,195,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2036,PSIVISSIG0002_2036,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,155,0,Death,NA,DEATH
PSIVISSIG0002,2037,PSIVISSIG0002_2037,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1020,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2038,PSIVISSIG0002_2038,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1089,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2039,PSIVISSIG0002_2039,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,1,Ongoing on first next-line therapy,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,2040,PSIVISSIG0002_2040,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,936,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,2041,PSIVISSIG0002_2041,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1085,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2042,PSIVISSIG0002_2042,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,521,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2043,PSIVISSIG0002_2043,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,872,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2044,PSIVISSIG0002_2044,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1312,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2045,PSIVISSIG0002_2045,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1315,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2046,PSIVISSIG0002_2046,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1406,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2047,PSIVISSIG0002_2047,43,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,61,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,2048,PSIVISSIG0002_2048,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1478,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2049,PSIVISSIG0002_2049,46,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,263,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2050,PSIVISSIG0002_2050,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,131,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2051,PSIVISSIG0002_2051,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1684,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2052,PSIVISSIG0002_2052,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1923,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2053,PSIVISSIG0002_2053,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,656,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2054,PSIVISSIG0002_2054,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,753,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2055,PSIVISSIG0002_2055,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,178,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2056,PSIVISSIG0002_2056,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,903,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2057,PSIVISSIG0002_2057,41,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,503,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2058,PSIVISSIG0002_2058,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,581,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2059,PSIVISSIG0002_2059,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,378,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2060,PSIVISSIG0002_2060,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,926,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2061,PSIVISSIG0002_2061,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,785,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2062,PSIVISSIG0002_2062,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,666,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2063,PSIVISSIG0002_2063,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,624,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2064,PSIVISSIG0002_2064,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1165,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2065,PSIVISSIG0002_2065,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,50,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2066,PSIVISSIG0002_2066,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1462,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2067,PSIVISSIG0002_2067,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,763,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2068,PSIVISSIG0002_2068,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,137,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2069,PSIVISSIG0002_2069,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,265,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2070,PSIVISSIG0002_2070,55,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1059,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2071,PSIVISSIG0002_2071,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,741,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2072,PSIVISSIG0002_2072,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,893,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2073,PSIVISSIG0002_2073,59,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,384,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,2074,PSIVISSIG0002_2074,79,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,641,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2075,PSIVISSIG0002_2075,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,383,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2076,PSIVISSIG0002_2076,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,829,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2077,PSIVISSIG0002_2077,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,448,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2078,PSIVISSIG0002_2078,35,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,660,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2079,PSIVISSIG0002_2079,56,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,211,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2080,PSIVISSIG0002_2080,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1353,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2081,PSIVISSIG0002_2081,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,813,1,No next-line therapy initiated,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2082,PSIVISSIG0002_2082,60,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,359,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2083,PSIVISSIG0002_2083,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,593,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2084,PSIVISSIG0002_2084,60,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,317,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2085,PSIVISSIG0002_2085,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1366,0,PD,NA,ADVERSE EVENT
PSIVISSIG0002,2086,PSIVISSIG0002_2086,71,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,0,Death,NA,PHYSICIAN DECISION
PSIVISSIG0002,2087,PSIVISSIG0002_2087,69,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,300,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2088,PSIVISSIG0002_2088,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,429,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2089,PSIVISSIG0002_2089,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,375,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2090,PSIVISSIG0002_2090,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,684,0,PD,NA,PHYSICIAN DECISION
PSIVISSIG0002,2091,PSIVISSIG0002_2091,44,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,243,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2092,PSIVISSIG0002_2092,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,157,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2093,PSIVISSIG0002_2093,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,244,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2094,PSIVISSIG0002_2094,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,385,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2095,PSIVISSIG0002_2095,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1720,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2096,PSIVISSIG0002_2096,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1361,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2097,PSIVISSIG0002_2097,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,469,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2098,PSIVISSIG0002_2098,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,141,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2099,PSIVISSIG0002_2099,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,295,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2100,PSIVISSIG0002_2100,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,621,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2101,PSIVISSIG0002_2101,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,744,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2102,PSIVISSIG0002_2102,87,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,787,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2103,PSIVISSIG0002_2103,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,306,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2104,PSIVISSIG0002_2104,57,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,570,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2105,PSIVISSIG0002_2105,60,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,735,1,No next-line therapy initiated,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,2106,PSIVISSIG0002_2106,58,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,398,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,2107,PSIVISSIG0002_2107,56,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,679,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2108,PSIVISSIG0002_2108,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1078,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2109,PSIVISSIG0002_2109,37,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,614,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2110,PSIVISSIG0002_2110,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,738,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2111,PSIVISSIG0002_2111,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,599,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2112,PSIVISSIG0002_2112,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,189,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2113,PSIVISSIG0002_2113,62,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,311,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2114,PSIVISSIG0002_2114,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,798,1,Ongoing on first next-line therapy,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2115,PSIVISSIG0002_2115,76,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,636,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2116,PSIVISSIG0002_2116,48,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,165,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2117,PSIVISSIG0002_2117,67,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,182,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2118,PSIVISSIG0002_2118,73,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1169,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2119,PSIVISSIG0002_2119,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1487,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2120,PSIVISSIG0002_2120,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,906,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2121,PSIVISSIG0002_2121,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,741,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2122,PSIVISSIG0002_2122,72,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,571,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2123,PSIVISSIG0002_2123,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,255,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2124,PSIVISSIG0002_2124,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,691,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2125,PSIVISSIG0002_2125,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,451,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2126,PSIVISSIG0002_2126,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1404,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2127,PSIVISSIG0002_2127,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1011,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2128,PSIVISSIG0002_2128,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,849,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2129,PSIVISSIG0002_2129,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,434,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2130,PSIVISSIG0002_2130,58,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,909,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2131,PSIVISSIG0002_2131,63,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,664,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2132,PSIVISSIG0002_2132,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1687,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2133,PSIVISSIG0002_2133,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,68,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2134,PSIVISSIG0002_2134,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,846,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2135,PSIVISSIG0002_2135,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,939,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2136,PSIVISSIG0002_2136,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,813,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2137,PSIVISSIG0002_2137,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,571,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2138,PSIVISSIG0002_2138,56,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,754,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2139,PSIVISSIG0002_2139,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1210,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2140,PSIVISSIG0002_2140,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,617,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2141,PSIVISSIG0002_2141,57,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,570,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2142,PSIVISSIG0002_2142,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1451,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2143,PSIVISSIG0002_2143,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,781,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2144,PSIVISSIG0002_2144,66,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1081,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2145,PSIVISSIG0002_2145,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,755,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2146,PSIVISSIG0002_2146,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,621,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2147,PSIVISSIG0002_2147,58,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,171,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2148,PSIVISSIG0002_2148,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,359,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2149,PSIVISSIG0002_2149,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1191,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2150,PSIVISSIG0002_2150,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,245,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2151,PSIVISSIG0002_2151,55,Positive,1,Hormone receptor positive,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1075,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2152,PSIVISSIG0002_2152,59,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1409,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2153,PSIVISSIG0002_2153,64,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,300,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2154,PSIVISSIG0002_2154,55,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,19,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2155,PSIVISSIG0002_2155,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1074,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2156,PSIVISSIG0002_2156,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,155,0,Death,NA,DEATH
PSIVISSIG0002,2157,PSIVISSIG0002_2157,44,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,410,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2158,PSIVISSIG0002_2158,61,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,403,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2159,PSIVISSIG0002_2159,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,807,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2160,PSIVISSIG0002_2160,71,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,891,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2161,PSIVISSIG0002_2161,52,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,72,1,Lost to follow-up,Censored at the last contact date,PROTOCOL DEVIATION
PSIVISSIG0002,2162,PSIVISSIG0002_2162,69,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,283,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2163,PSIVISSIG0002_2163,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,458,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2164,PSIVISSIG0002_2164,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,842,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2165,PSIVISSIG0002_2165,67,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1299,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2166,PSIVISSIG0002_2166,80,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,76,1,Lost to follow-up,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,2167,PSIVISSIG0002_2167,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,563,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2168,PSIVISSIG0002_2168,54,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,574,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2169,PSIVISSIG0002_2169,76,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,903,0,Death,NA,DEATH
PSIVISSIG0002,2170,PSIVISSIG0002_2170,72,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,702,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2171,PSIVISSIG0002_2171,77,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,875,1,Lost to follow-up,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2172,PSIVISSIG0002_2172,68,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1011,1,No next-line therapy initiated,Censored at the last contact date,PHYSICIAN DECISION
PSIVISSIG0002,2173,PSIVISSIG0002_2173,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,352,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2174,PSIVISSIG0002_2174,66,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,500,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2175,PSIVISSIG0002_2175,55,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,737,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2176,PSIVISSIG0002_2176,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1011,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2177,PSIVISSIG0002_2177,75,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,319,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2178,PSIVISSIG0002_2178,45,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,288,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2179,PSIVISSIG0002_2179,54,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,841,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2180,PSIVISSIG0002_2180,69,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,301,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2181,PSIVISSIG0002_2181,74,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,314,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2182,PSIVISSIG0002_2182,63,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,293,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2183,PSIVISSIG0002_2183,69,Negative,2,Hormone receptor negative,PRIOR USE,1,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,296,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2184,PSIVISSIG0002_2184,71,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,572,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2185,PSIVISSIG0002_2185,65,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1356,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2186,PSIVISSIG0002_2186,70,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,980,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2187,PSIVISSIG0002_2187,46,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,216,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2188,PSIVISSIG0002_2188,50,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,645,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2189,PSIVISSIG0002_2189,62,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1319,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2190,PSIVISSIG0002_2190,70,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,33,1,No next-line therapy initiated,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2191,PSIVISSIG0002_2191,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1392,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2192,PSIVISSIG0002_2192,88,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,348,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2193,PSIVISSIG0002_2193,74,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,591,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2194,PSIVISSIG0002_2194,64,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,728,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2195,PSIVISSIG0002_2195,51,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,340,1,No next-line therapy initiated,Censored at the last contact date,NA
PSIVISSIG0002,2196,PSIVISSIG0002_2196,57,Positive,1,Hormone receptor positive,NO PRIOR USE,2,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,468,0,PD,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2197,PSIVISSIG0002_2197,61,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,644,1,Ongoing on first next-line therapy,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2198,PSIVISSIG0002_2198,65,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,857,0,Death,NA,PROGRESSIVE DISEASE
PSIVISSIG0002,2199,PSIVISSIG0002_2199,50,Negative,2,Hormone receptor negative,NO PRIOR USE,2,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,162,0,Death,NA,PROGRESSIVE DISEASE
